US20150343060A1 - Treatment of circulating tumor cells using an extracorporeal device - Google Patents
Treatment of circulating tumor cells using an extracorporeal device Download PDFInfo
- Publication number
- US20150343060A1 US20150343060A1 US14/728,204 US201514728204A US2015343060A1 US 20150343060 A1 US20150343060 A1 US 20150343060A1 US 201514728204 A US201514728204 A US 201514728204A US 2015343060 A1 US2015343060 A1 US 2015343060A1
- Authority
- US
- United States
- Prior art keywords
- subject
- blood
- ctcs
- ctc
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 title claims abstract description 96
- 238000011282 treatment Methods 0.000 title claims description 30
- 238000000034 method Methods 0.000 claims abstract description 66
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 230000008685 targeting Effects 0.000 claims abstract description 39
- 239000000427 antigen Substances 0.000 claims abstract description 21
- 102000036639 antigens Human genes 0.000 claims abstract description 21
- 108091007433 antigens Proteins 0.000 claims abstract description 21
- 230000005291 magnetic effect Effects 0.000 claims abstract description 15
- 239000008280 blood Substances 0.000 claims description 71
- 210000004369 blood Anatomy 0.000 claims description 70
- 239000003795 chemical substances by application Substances 0.000 claims description 46
- 201000011510 cancer Diseases 0.000 claims description 27
- 230000001678 irradiating effect Effects 0.000 claims description 22
- 230000030833 cell death Effects 0.000 claims description 18
- 230000006907 apoptotic process Effects 0.000 claims description 17
- 230000017074 necrotic cell death Effects 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 239000001007 phthalocyanine dye Substances 0.000 claims description 13
- 230000004900 autophagic degradation Effects 0.000 claims description 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 230000005284 excitation Effects 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 239000003146 anticoagulant agent Substances 0.000 claims description 8
- 229940127219 anticoagulant drug Drugs 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 6
- 239000006249 magnetic particle Substances 0.000 claims description 6
- 238000002271 resection Methods 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 150000003384 small molecules Chemical class 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 abstract description 103
- 239000000203 mixture Substances 0.000 abstract description 9
- 239000000523 sample Substances 0.000 description 33
- 238000002428 photodynamic therapy Methods 0.000 description 18
- 239000003504 photosensitizing agent Substances 0.000 description 13
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 10
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 10
- -1 Twist Proteins 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000027455 binding Effects 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 229960001972 panitumumab Drugs 0.000 description 8
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000009467 reduction Effects 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 102100032912 CD44 antigen Human genes 0.000 description 5
- 102000000905 Cadherin Human genes 0.000 description 5
- 108050007957 Cadherin Proteins 0.000 description 5
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 5
- 102000015689 E-Selectin Human genes 0.000 description 5
- 108010024212 E-Selectin Proteins 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 5
- 108060006698 EGF receptor Proteins 0.000 description 5
- 101150029707 ERBB2 gene Proteins 0.000 description 5
- 102000016359 Fibronectins Human genes 0.000 description 5
- 108010067306 Fibronectins Proteins 0.000 description 5
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 5
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 5
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 5
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 5
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 5
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 5
- 108010066327 Keratin-18 Proteins 0.000 description 5
- 108010066302 Keratin-19 Proteins 0.000 description 5
- 108010070511 Keratin-8 Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 102100034256 Mucin-1 Human genes 0.000 description 5
- 108090000054 Syndecan-2 Proteins 0.000 description 5
- 102000013127 Vimentin Human genes 0.000 description 5
- 108010065472 Vimentin Proteins 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000002572 peristaltic effect Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000005048 vimentin Anatomy 0.000 description 5
- 229960002749 aminolevulinic acid Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 238000001126 phototherapy Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 206010003226 Arteriovenous fistula Diseases 0.000 description 2
- 101150084967 EPCAM gene Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960001123 epoprostenol Drugs 0.000 description 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- LZYXPFZBAZTOCH-UHFFFAOYSA-N hexyl 5-amino-4-oxopentanoate;hydron;chloride Chemical compound Cl.CCCCCCOC(=O)CCC(=O)CN LZYXPFZBAZTOCH-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229940118199 levulan Drugs 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 229940109328 photofrin Drugs 0.000 description 2
- 230000002165 photosensitisation Effects 0.000 description 2
- 229940127293 prostanoid Drugs 0.000 description 2
- 150000003814 prostanoids Chemical class 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 229960001790 sodium citrate Drugs 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003868 thrombin inhibitor Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ATNMPCPGYQSWBN-REOHCLBHSA-N (3s)-3-amino-4-chloro-4-oxobutanoic acid Chemical compound ClC(=O)[C@@H](N)CC(O)=O ATNMPCPGYQSWBN-REOHCLBHSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- MVBCOYVJSZKRIV-UHFFFAOYSA-N 4-[10,15-diphenyl-20-(4-sulfophenyl)-2,3,22,24-tetrahydroporphyrin-5-yl]benzenesulfonic acid Chemical compound C1=CC(S(=O)(=O)O)=CC=C1C(C1=CC=C(N1)C(C=1C=CC=CC=1)=C1C=CC(=N1)C(C=1C=CC=CC=1)=C1C=CC(N1)=C1C=2C=CC(=CC=2)S(O)(=O)=O)=C2N=C1CC2 MVBCOYVJSZKRIV-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Chemical class 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- VSEIDZLLWQQJGK-CHOZPQDDSA-N CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O Chemical compound CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O VSEIDZLLWQQJGK-CHOZPQDDSA-N 0.000 description 1
- WXYONNPYOAODAW-UHFFFAOYSA-J C[Si](C)(CCC[N+](CCCS(=O)(=O)[O-])(CCCS(=O)(=O)O[Na])CCCS(=O)(=O)O[Na])O[Si]123(O[Si](C)(C)CCC[N+](CCCS(=O)(=O)[O-])(CCCS(=O)(=O)O[Na])CCCS(=O)(=O)O[Na])N4C5=C6C=CC=CC6=C4/N=C4/C6=C(C=CC=C6OCCCOC(=O)NCCCCCC(=O)O)C(=N41)/N=C1/C4=C(C=CC=C4)/C(=N/C4=N2C(=N5)C2=C4C=CC=C2)N13 Chemical compound C[Si](C)(CCC[N+](CCCS(=O)(=O)[O-])(CCCS(=O)(=O)O[Na])CCCS(=O)(=O)O[Na])O[Si]123(O[Si](C)(C)CCC[N+](CCCS(=O)(=O)[O-])(CCCS(=O)(=O)O[Na])CCCS(=O)(=O)O[Na])N4C5=C6C=CC=CC6=C4/N=C4/C6=C(C=CC=C6OCCCOC(=O)NCCCCCC(=O)O)C(=N41)/N=C1/C4=C(C=CC=C4)/C(=N/C4=N2C(=N5)C2=C4C=CC=C2)N13 WXYONNPYOAODAW-UHFFFAOYSA-J 0.000 description 1
- OHCFWTOZJNVHAS-UHFFFAOYSA-J C[Si](C)(CCC[N+](CCCS(=O)(=O)[O-])(CCCS(=O)(=O)O[Na])CCCS(=O)(=O)O[Na])O[Si]123(O[Si](C)(C)CCC[N+](CCCS(=O)(=O)[O-])(CCCS(=O)(=O)O[Na])CCCS(=O)(=O)O[Na])N4C5=C6C=CC=CC6=C4/N=C4/C6=C(C=CC=C6OCCCOC(=O)NCCCCCC(=O)ON6C(=O)CCC6=O)C(=N41)/N=C1/C4=C(C=CC=C4)/C(=N/C4=N2C(=N5)C2=C4C=CC=C2)N13 Chemical compound C[Si](C)(CCC[N+](CCCS(=O)(=O)[O-])(CCCS(=O)(=O)O[Na])CCCS(=O)(=O)O[Na])O[Si]123(O[Si](C)(C)CCC[N+](CCCS(=O)(=O)[O-])(CCCS(=O)(=O)O[Na])CCCS(=O)(=O)O[Na])N4C5=C6C=CC=CC6=C4/N=C4/C6=C(C=CC=C6OCCCOC(=O)NCCCCCC(=O)ON6C(=O)CCC6=O)C(=N41)/N=C1/C4=C(C=CC=C4)/C(=N/C4=N2C(=N5)C2=C4C=CC=C2)N13 OHCFWTOZJNVHAS-UHFFFAOYSA-J 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108091081406 G-quadruplex Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000009359 Sezary Syndrome Diseases 0.000 description 1
- 208000021388 Sezary disease Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 102000023852 carbohydrate binding proteins Human genes 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000013501 data transformation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000011554 ferrofluid Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910000833 kovar Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- YUUAYBAIHCDHHD-UHFFFAOYSA-N methyl 5-aminolevulinate Chemical compound COC(=O)CCC(=O)CN YUUAYBAIHCDHHD-UHFFFAOYSA-N 0.000 description 1
- UJYSYPVQHFNBML-UHFFFAOYSA-N methyl 5-aminolevulinate hydrochloride Chemical compound [Cl-].COC(=O)CCC(=O)C[NH3+] UJYSYPVQHFNBML-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 229940112139 metvixia Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- WIQKYZYFTAEWBF-UHFFFAOYSA-L motexafin lutetium hydrate Chemical compound O.[Lu+3].CC([O-])=O.CC([O-])=O.C1=C([N-]2)C(CC)=C(CC)C2=CC(C(=C2C)CCCO)=NC2=CN=C2C=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=NC=C2C(C)=C(CCCO)C1=N2 WIQKYZYFTAEWBF-UHFFFAOYSA-L 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- MCTOGTBIQBEIBZ-QHWUVJKOSA-K photrex Chemical compound CCOC(=O)C([C@@]1([C@H]2C)CC)=CC3=C1N([Sn](N14)(Cl)Cl)C2=CC(C(=C2C)CC)=NC2=CC1=C(CC)C(C)=C4C=C1C(CC)=C(C)C3=N1 MCTOGTBIQBEIBZ-QHWUVJKOSA-K 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- JACPFCQFVIAGDN-UHFFFAOYSA-M sipc iv Chemical compound [OH-].[Si+4].CN(C)CCC[Si](C)(C)[O-].C=1C=CC=C(C(N=C2[N-]C(C3=CC=CC=C32)=N2)=N3)C=1C3=CC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 JACPFCQFVIAGDN-UHFFFAOYSA-M 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229950010924 talaporfin Drugs 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940061392 visudyne Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 231100000054 whole-body exposure Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3618—Magnetic separation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
- A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
- A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
- A61M1/3686—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents by removing photoactive agents after irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
Definitions
- Tumor metastasis is the process in which cancer cells spread from the site of a primary solid tumor to one or more other organs in the body.
- the cancer cells such as circulating tumor cells (CTCs)
- CTCs circulating tumor cells
- Solid tumors are treated by therapies including surgery, radiotherapy, chemotherapy and targeted antibody therapy.
- Photoimmunotherapy using photosensitizing moiety or biomolecule-fluorophore conjugates has been described as a possible treatment as well (see, e.g., U.S. Pat. No. 8,524,239).
- Photosensitizing antibody-fluorophore conjugates can utilize phthalocyanine dyes, such as IRDye® 700DX (LI-COR Biosciences, Lincoln, Nebr.) which has low sensitivity to photobleaching and is highly photostable (see, e.g., U.S. Pat. No. 7,005,518).
- phthalocyanine dyes such as IRDye® 700DX (LI-COR Biosciences, Lincoln, Nebr.) which has low sensitivity to photobleaching and is highly photostable (see, e.g., U.S. Pat. No. 7,005,518).
- These dyes can be conjugated to various biomolecules, such as antibodies or fragments thereof, antibodies, nanobodies, Affibodies®, diabodies, minibodies, antigens, ligands, proteins, peptides, carbohydrates, nucleic acids, small molecules, pseudovirion, etc.
- the phthalocyanine dye When exposed to excitation light, the phthalocyanine dye generates a cytotoxic singlet oxygen that can induce cell death, such as through apoptosis, necrosis or autophagy. Two types of reactions occur, Type I generates radicals and Type II generates singlet oxygen. Both radicals and singlet oxygen cause oxidative destruction of tissues. It has been shown that the administration of photodynamic therapy using IRDye® 700DX-anti-HER2 + antibodies can decrease the size of HER2 + solid tumors in a mouse model (Mitsunaga et al., Nat. Med., 2011, 17(12):1685-1691).
- Photodynamic therapy with photosensitizer can be performed with different forms of light sources (see, e.g., U.S. Pat. Nos. 5,976,175 and 8,175,687) to enable excitation light reaching different body locations.
- Whole body exposure with tanning bed (U.S. Pat. No. 6,896,693) or long-term treatment with wearable devices (U.S. Pat. No. 7,850,720) has been demonstrated.
- One of key factors in these kinds of methods is the extensive extinction of excitation light when passing through skins, soft tissues, or organs.
- Extracorporeal blood treatment eliminates the concern of light absorption through thick tissue layers.
- extracorporeal devices have been applied to patients for different treatment such as hemodialysis, extracorporeal oxygenation, CO 2 removal, and apheresis, etc.
- the knowledge on extracorporeal circulation is thus well established and broadly applied.
- photopheresis utilizes separation of blood compositions and applies UV light to the concentrated part (e.g. white blood cells) before returning the recombined blood components to the patient.
- the photopheresis or extracorporeal photochemotherapy see, e.g., U.S. Patent Publication Nos.
- the number of CTCs in a patient can be estimated via the CELLSEARCH® System (Janssen Diagnostics, LLC, Raritan, N.J.).
- the system utilizes ferrofluid nanoparticles with epithelial cell adhesion targeting antibodies to enumerate CTCs from the bulk of 7.5 ml blood samples.
- the CTCs are then distinguished with immunofluoresence dyes under a microscopic imaging system for diagnosis purpose.
- the system renders the monitoring of metastatic cancer patients throughout treatment to making informed clinical decisions.
- a method for inducing apoptosis, necrosis or autophagy resulting in cell death of circulating tumor cells (CTCs) in a subject comprises (a) administering to the subject's blood a therapeutically effective agent comprising a near-infrared phthalocyanine dye conjugated to an moiety or biomolecule that specifically binds to CTCs; (b) ex vivo irradiating the subject's blood with an appropriate excitation light in an amount to effectively induce apoptosis, necrosis and/or autophagy in the CTCs; and (c) re-introducing the treated blood into the subject.
- a therapeutically effective agent comprising a near-infrared phthalocyanine dye conjugated to an moiety or biomolecule that specifically binds to CTCs
- ex vivo irradiating the subject's blood with an appropriate excitation light in an amount to effectively induce apoptosis, necrosis and/or autophagy in the CTCs
- the subject has a solid tumor or has had a solid tumor.
- the solid tumor is a breast tumor, colorectal tumor, lung tumor, prostate tumor, ovarian tumor, pancreatic tumor, liver tumor, or bladder tumor.
- the phthalocyanine dye is IRDyeTM 700DX. In some embodiments, the light has a wavelength of about 660 to 740 nm.
- the moiety or biomolecule specifically binds a CTC antigen.
- the CTC antigen is selected from the group consisting of epithelial cell adhesion molecule (EpCAM), cytokeratin 8, cytokeratin 18, cytokeratin 19, E-cadherin, fibronectin, vimentin, MUC1, Her2, Twist, E-selectin, HSPG, CD44, octreoate, and others.
- the therapeutically effective agent is administered at the time of anticoagulant administration with heparin, sodium citrate, thrombin inhibitors, prostacyclin and other prostanoids or other effective anticoagulants.
- un-bound therapeutically effective agent will be reduced or removed from blood via filtration or dialyzer or methods that involved molecular movement.
- a method of extracorporeal treatment of cancer in a subject having circulating tumor cells comprises: (a) intravenously administering a therapeutically effective agent comprising a phthalocyanine dye conjugated to a targeting moiety that specifically binds to CTCs; (b) ex vivo irradiating the subject's blood with a light (e.g., wavelength of 660 to 740 nm) in an amount to effectively induce apoptosis, necrosis or autophagy in CTCs; and (c) re-introducing the irradiated blood into the subject, thereby treating cancer in the subject.
- a light e.g., wavelength of 660 to 740 nm
- step (b) and/or (c) are performed using an extracorporeal device.
- the subject has undergone solid tumor resection.
- the therapeutic agent is IRDye® 700DX.
- the light has a wavelength of 660 to 740 nm.
- the antibody specifically binds a CTC antigen.
- the CTC antigen is selected from the group consisting of epithelial cell adhesion molecule (EpCAM), cytokeratin 8, cytokeratin 18, cytokeratin 19, E-cadherin, fibronectin, vimentin, MUC1, Her2, Twist, E-selectin, HSPG, CD44, octreoate, and others.
- the therapeutically effective agent is administered at the time of anticoagulant administration with heparin, sodium citrate, thrombin inhibitors, prostacyclin and other prostanoids or other effective anticoagulants.
- unbound therapeutically effective agent will be reduced or removed from blood via filtration or dialyzer or methods that involved molecular movement.
- ex vivo irradiating is performed using an extracorporeal device.
- a method of extracorporeal treatment of cancer in a subject having CTCs comprises: (a) administering a targeting agent comprising a magnetic particle conjugated to a biomolecule that specifically binds to CTCs; (b) ex vivo treatment of CTCs with an extracorporeal circuit to separate the particle-bound CTCs from blood stream with magnetic influence(s); and (c) re-introducing the treated blood into the subject, thereby mitigate the number of CTCs in the subject.
- the treatment agent is introduced ex vivo through the extracorporeal device.
- the subject has undergone solid tumor resection.
- the antibody specifically binds a CTC antigen.
- the CTC antigen is selected from the group consisting of epithelial cell adhesion molecule (EpCAM), cytokeratin 8, cytokeratin 18, cytokeratin 19, E-cadherin, fibronectin, vimentin, MUC1, Her2, Twist, E-selectin, HSPG, CD44, octreoate, and others.
- the magnetic particle-targeted CTCs is removed or separated from blood via methods that involve molecular movement such as the influence of magnetic field(s).
- a therapeutically effective composition comprising a therapeutically effective agent comprising a phthanlocyanine dye conjugated to a circulating tumor cell (CTC) targeting moiety or biomolecule that specifically binds to a CTC.
- CTC circulating tumor cell
- the phthalocyanine dye is IRDye® 700DX.
- the targeting moiety or biomolecule specifically binds a CTC antigen.
- the CTC antigen is selected from the group consisting of epithelial cell adhesion molecule (EpCAM), cytokeratin 8, cytokeratin 18, cytokeratin 19, E-cadherin, fibronectin, vimentin, MUC1, Her2, Twist, E-selectin, HSPG, CD44, octreoate, and others.
- EpCAM epithelial cell adhesion molecule
- cytokeratin 8 cytokeratin 18, cytokeratin 19, E-cadherin, fibronectin, vimentin, MUC1, Her2, Twist, E-selectin, HSPG, CD44, octreoate, and others.
- FIG. 1 is a schematic illustration of an exemplary embodiment in which the CTC extracorporeal photodynamic treatment is performed in the extracorporeal circuit.
- FIG. 2 illustrates an exemplary embodiment of the methods with CTC targeting magnetic particles which attaches to CTCs and renders the removal of CTCs with magnetic influence (e.g., a magnetic field).
- CTC targeting magnetic particles which attaches to CTCs and renders the removal of CTCs with magnetic influence (e.g., a magnetic field).
- FIGS. 3A-E show a reduction in the number of targeted cancer cells after exposure to irradiating light at 8 J/cm 2 or 16 J/cm 2 .
- FIGS. 3A-C show control data and FIGS. 3D-E show exposure to 8 J/cm 2 or 16 J/cm 2 , respectively.
- FIGS. 4A-D show a reduction in the number of targeted cancer cells after exposure to irradiating light at 670 nm to 700 nm at 8 J/cm 2 or 16 J/cm 2 was made through 1 mm whole blood.
- FIGS. 4A-B present control data and FIGS. 4C-D show exposure to 8 J/cm 2 or 16 J/cm 2 , respectively.
- FIGS. 5A-B show the IRDye® 700DX-EGF probe binding to A431 cells at two concentrations for two different time periods.
- A431 cells received a peristaltic flow of 1.36 mL/min of IRDye® 700DX-EGF at a concentration of 0.2 ⁇ M for 15 min ( FIG. 5A ).
- A431 cells received a peristaltic flow of 1.36 mL/min of IRDye®700DX-EGF at a concentration of 0.5 ⁇ M for 5 min ( FIG. 5B ).
- FIGS. 6A-6D show images of A431 cells incubated for 5 minutes with variable concentrations of IRDye 700DX®-EGF and then irradiated at 4 J/cm 2 .
- FIG. 6A shows the cells during the incubation of 0.5 ⁇ M of probe and
- FIG. 6B shows the cells after irradiation.
- FIG. 6C shows the cells incubated with 2 ⁇ M of probe.
- FIG. 6D shows these cells after irradiation.
- FIGS. 7A-7D provides images of A431 cells incubated for 10 minutes with variable concentrations of IRDye 700DX®-EGF and then irradiated at 16 J/cm 2 .
- Cells that were incubated with 0.5 ⁇ M of probe are shown in FIG. 7A .
- FIG. 7B shows these cells after irradiation.
- FIG. 7C shows cells treated with 2 ⁇ M of probe and
- FIG. 7D shows the cells after irradiation treatment.
- FIG. 8 illustrates that the percent cell vitality was lower for irradiation treatments of 16 J/cm 2 (e.g., treatments 3, 4, 7 and 8) compared to those of 4 J/cm 2 . Within the parameters tested, cell vitality was independent of probe concentration and probe incubation times.
- FIGS. 9A-C provides data of the statistical analysis performed.
- FIG. 9A shows the Box-Cox plot indicating that no transformation of data was required.
- FIG. 9B shows the normal probability plot of residuals that indicates that the residuals followed a normal distribution and were a good fit.
- FIG. 9C shows the ANOVA analysis.
- FIG. 10 provides a graph of the percent cell vitality of tumor cells treated with IRDye® 700DX-EGF or IRDye® 700DX-panitumumab and irradiated at 24 J/cm 2 . The cells were incubated for 5 minutes, 10 minutes or 20 minutes with the probe.
- FIGS. 11A-C provides images of the cells after irradiation at 24 J/cm 2 .
- the cells exhibited morphological blebbing which is associated with apoptosis and/or necrosis (see, white arrows).
- the present invention relates to compositions and methods for the elimination of CTCs circulating in the blood of an individual. More particularly, the invention involves the use of a continuous-flow, extracorporeal device that treats the cells with IRDye®-targeting agents or magnetic particle-targeting agent to either trigger CTC cell death or enable the removal of CTCs from the blood stream before returning the treated blood to the body.
- Cell death of CTCs can be induced with an IRDye®700DX-targeting agent and the appropriate light exposure.
- the CTCs can be removed from the blood using a magnetic particle-targeting agent and a magnetic influence.
- CTC targeting moiety refers to any compound, molecule, or fragment thereof that can specifically bind to to the surface of a circulating tumor cell (CTC), e.g., any component present on the surface of a CTC, and/or tumor cell matter, e.g., any matter or component thereof that is derived, originated, or secreted from a tumor cell.
- CTC circulating tumor cell
- Molecules that can be used as CTC targeting moieties include, but are not limited to, peptides, polypeptides, proteins, peptidomimetics, ligands, antigens, antibodies, antibody fragments (e.g., antigen binding fragments of antibodies), nanobodies, Affibodies®, diabodies, minibodies, carbohydrate-binding protein, e.g., a lectin, glycoproteins, glycoprotein-binding molecules, amino acids, carbohydrates (including mono-, di-, tri- and poly-saccharides), lipids, steroids, hormones, lipid-binding molecules, cofactors, nucleosides, nucleotides, nucleic acids (e.g., DNA or RNA, analogues and derivatives of nucleic acids, or aptamers), peptidoglycans, lipopolysaccharides, small molecules, and any combinations thereof.
- carbohydrate-binding protein e.g., a lect
- antibody refers to a polypeptide comprising at least a light chain or heavy chain immunoglobulin variable region which specifically recognizes and binds an epitope of an antigen, such as a tumor-specific protein.
- Antibodies are composed of a heavy and a light chain, each of which has a variable region, termed the variable heavy (V H ) region and the variable light (V L ) region. Together, the V H region and the V L region are responsible for binding the antigen recognized by the antibody.
- Antibodies include intact immunoglobulins and the variants and portions of antibodies well known in the art, such as Fab fragments, Fab′ fragments, F(ab)′ 2 fragments, single chain Fv proteins (“scFv”), and disulfide stabilized Fv proteins (“dsFv”).
- scFv protein is a fusion protein in which a light chain variable region of an immunoglobulin and a heavy chain variable region of an immunoglobulin are bound by a linker, while in dsFvs, the chains have been mutated to introduce a disulfide bond to stabilize the association of the chains.
- the term also includes genetically engineered forms such as chimeric antibodies (for example, humanized murine antibodies), heteroconjugate antibodies (such as, bispecific antibodies). See also, Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, Ill.); Kuby, J., Immunology, 3rd Ed., W.H. Freeman & Co., New York, 1997.
- the term “IRDye® 700DX” or “IR700” refers to a dye having the preferred NHS ester linkage to allow for conjugation to a CTC targeting moiety.
- the CTC targeting moiety such as an antibody has a primary amine (e.g., an amino group) wherein the NHS ester and the amino group react to form an amide bond, linking the targeting moiety such as an antibody to 700DX.
- the NHS ester IRDye® 700DX has the following formula:
- the dye is commercially available from LI-COR (Lincoln, Nebr.).
- Amino-reactive IRDye® 700DX is a relatively hydrophilic dye and can be covalently conjugated with an antibody using the NHS ester of IRDye® 700DX.
- Other variations of IRDye 700Dx are disclosed in U.S. Pat. No. 7,005,518 (incorporated herein by reference), and those too are useful in the present invention.
- the carboxylate derivative has the following name and structure, silicate(5-), bis[N[3-[(hydroxy-.kappa.O)dimethylsilyl]propyl]-3-sulfo-N,N-bis(3-sulfopropyl)-1-propanaminiumato(4-)][6-[[[3-[(29H,31H-phthalocyanin-yl-.kappa.N29,.kappa.N30,.kappa.N31,.kappa.N32)oxy]propoxy]carbonyl]amino]hexanoato(3-)]-, sodium (1:5); CAS Registry Number: [1623074-46-3]:
- photodynamic therapy refers to a molecular targeted therapy that utilizes a target-specific photosensitizer agent, based on a near infrared (NIR) phthalocyanine dye, IRDye® 700DX, conjugated to a targeting moiety that specifically bind to a cell surface protein.
- NIR near infrared
- IRDye® 700DX conjugated to a targeting moiety that specifically bind to a cell surface protein.
- the cell surface protein such as EpCam is found specifically on circulating tumor cells, and thus photodynamic therapy can be used to kill such cells.
- Cell death of the cells can be induced when the IRDye® 700DX-anti-EpCam antibody binds to the cells and the cells are irradiated with the proper excitation light.
- the cytotoxic agent is produced by one of the two different processes called Type I or Type II PDT pathways. Type I generates radicals and Type II generates singlet oxygen. Both radicals and singlet oxygen cause oxidative destruction of tissues
- Non-targeted options for PDT include sensitizers, porphyrins, chlorophylls and dyes.
- Non-limiting examples of useful photosensitizers include aminolevulinic acid (ALA), silicon phthalocyanine Pc 4, m-tetrahydroxyphenylchlorin (mTHPC), mono-L-aspartyl chlorine 6 (NPe6), and methylene blue.
- ALA aminolevulinic acid
- mTHPC silicon phthalocyanine Pc 4
- NPe6 mono-L-aspartyl chlorine 6
- methylene blue methylene blue
- Commercially photosensitizers available for clinical use include Allumera®, Photofrin®, Visudyne®, Levulan®, Foscan®, Metvix®, Hexvix®, Cysview®, and Laserphyrin®.
- photosensitizers in development include Antrin®, Photochlor®, Photosens, Photrex®, Lumacan®, Cevira®, Visonac®, BF-200 ALA®, Amphinex®, and Azadipyrromethene®.
- PDT agents include halogenated compounds, such as those described in, e.g., U.S. Patent Publication No.
- 2013/0231604 near-infrared light triggered upconversion nanoconstruct, such as those described in, e.g., Cui et al., ACS Nano, 2013, 7 (1), 676-688; hyaluronic acid-conjugated grapheme oxide/photosensitizer nanohybrids, such as those described in, e.g., Li et al., J. Mater. Chem. B, 2013, 1, 1678-1686, and aptamer-guided G-Quadruplex DNA carriers, such as those described in, e.g., Yuan et al., Angew. Chem. Int. Ed., 52: 13965-13969.
- near-infrared light triggered upconversion nanoconstruct such as those described in, e.g., Cui et al., ACS Nano, 2013, 7 (1), 676-688
- terapéuticaally effective amount refers to an amount of a composition that alone, or together with an additional therapeutic agent(s) (such as a chemotherapeutic agent) is sufficient to achieve a desired effect in a subject, or in a cell, being treated with the composition.
- the effective amount of the therapeutic composition can be dependent on several factors, including, but not limited to the subject or cells being treated, the particular therapeutic agent, and the manner of administration of the therapeutic composition.
- a therapeutically effective amount or concentration is sufficient to prevent advancement (such as metastasis), delay progression, or to cause regression of a disease, or which is capable of reducing symptoms caused by the disease, such as cancer.
- a therapeutically effective amount or concentration is sufficient to increase the survival time of a patient with a circulating tumor cell.
- extractor refers to an instrument that receives blood that is removed from a patient, processes (e.g., filters, purifies, treats, administers therapeutic agents to, etc.) the blood, and then returns the blood to the patient.
- processes e.g., filters, purifies, treats, administers therapeutic agents to, etc.
- magnetic particles includes beads, microbeads, and particles that a magnetic or paramagnetic.
- subject typically refers to humans, but also to other animals including, e.g., other primates, rodents, canines, felines, equines, ovines, porcines, and the like.
- the methods provided herein can be used to treat a cancer patient post tumor resection (e.g., tumor excision by surgery) or treatment by reducing the circulating tumor cells (CTCs) in the blood, and thus, reducing the chance of metastatic spread.
- Photodynamic therapy utilizes photosensitizers (e.g., photosensitizing agents or drugs) and light exposure to kill cancer cells.
- photosensitizers e.g., photosensitizing agents or drugs
- the photosensitizing agent, porfimer sodium e.g., Photofrin® is FDA approved for use in PDT to treat the symptoms of esophageal cancer and non-small cell lung cancer.
- Aminnolevulini acid (ALA or Levulan®) and methyl ester of ALA (Metvixia® cream) are FDA approved for skin or topical treatment for PDT. Most photosensitizing agents are not targeted and require irradiation of the whole body or a large region, which can result in unwanted cell death of normal tissues.
- an extracorporeal device that can circulate blood containing CTC targeted agents and to either induce CTC cell death (e.g., apoptosis, necrosis or autophagy) or to separate the CTCs from the blood returning to the body.
- CTC cell death e.g., apoptosis, necrosis or autophagy
- the cell death is induced by photodynamic therapy method for CTCs that employs an IRDye®-targeting agent that can be excited by an irradiating light of a wavelength from 660 nm to about 740 nm.
- the irradiated blood can be returned (e.g., reintroduced) to the subject where the subject's immune system can recognize the apoptotic and/or necrotic cells and target them for removal.
- the extracorporeal device is to circulate blood outside the body for the treatment of the agent targeted CTCs.
- targeted photosensitizing agents such as IRDye® 700DX-CTC moieties.
- Any targeting moiety e.g., an antibody or fragment thereof, nanobody, Affibody®, diabody, minibody, antigen, ligand, protein, peptide, carbohydrate, nucleic acids, or small molecule
- Any targeting moiety e.g., an antibody or fragment thereof, nanobody, Affibody®, diabody, minibody, antigen, ligand, protein, peptide, carbohydrate, nucleic acids, or small molecule
- the targeting moiety is specific for a protein expressed on the cell surface of a CTC.
- the cell surface protein can be selectively expressed on the surface of CTCs, and not other cells such as normal cells.
- the cell surface protein is epithelial cell adhesion molecule (EpCAM), cytokeratin 8, cytokeratin 18, cytokeratin 19, E-cadherin, fibronectin, vimentin, MUC1, Her2, Twist, E-selectin, HSPG, CD44, octreoate, and others.
- EpCam antibodies are available from, e.g., Abeam® (Cambridge, Mass.), Cell Signaling Technology® (Danvers, Mass.), Santa Cruz Biotechnology® (Santa Cruz, Calif.), and other companies.
- the generation and selection of antibodies not already commercially available for targeting circulating tumor cells in accordance with the present invention can be accomplished several ways. For example, one way is to express and/or purify a polypeptide of interest (i.e., antigen) using protein expression and purification methods known in the art, while another way is to synthesize the polypeptide of interest using solid phase peptide synthesis methods known in the art. See, e.g., Guide to Protein Purification , Murray P. Deutcher, ed., Meth. Enzymol ., Vol. 182 (1990); Solid Phase Peptide Synthesis , Greg B. Fields, ed., Meth. Enzymol ., Vol. 289 (1997); Kiso et al., Chem.
- binding fragments or Fab fragments which mimic (e.g., retain the functional binding regions of) antibodies can also be prepared from genetic information by various procedures. See, e.g., Antibody Engineering: A Practical Approach , Borrebaeck, Ed., Oxford University Press, Oxford (1995); and Huse et al., J. Immunol., 149:3914-3920 (1992).
- the CTC targeting agent (e.g., CTC targeting moiety) can be conjugated to a phthalocyanine dye, IRDye® 700DX (LI-COR, Lincoln, Nebr.).
- CTC targeting moieties are labeled with IRDye® 700DX according to the manufacturer's protocols and kits.
- Detailed descriptions of methods for producing IRDye® 700DX-conjugates are found in, e.g., Kovar et al, Biochemistry—Faculty Publications, 2007, paper 9; Mitsunaga et al., Nature Medicine, 2011, 17:1685-1691; Peng et al., Proceedings of SPIE, 2006, 6097; U.S. Pat. Nos. 7,005,518 and 8,524,239; and U.S. Patent Application Publication No. 2013/0336995, the disclosures of each are herein incorporated in their entirety for all purposes.
- the IRDye®700DX-CTC moiety can be administered to the subject's blood in the blood circuit of the extracorporeal device.
- the targeting agent is injected into the blood that has exited the subject prior to treatment by the excitation light.
- the dose of IRDye® 700DX-CTC moiety or biomolecle can be removed or cleared from the blood before returning to the subject.
- the removal or clearance methods can be mechanisms involved in molecular movement or attachment to isolate the agent from the blood stream so that the returning blood contains minimal amount of the therapeutic agent.
- the IRDye® 700DX-CTC moiety or biomolecule can be administered systemically using any method known in the art, for example to subjects having a tumor, such as a cancer, or who has had tumor resection (e.g., tumor removal, for example, by surgery).
- a tumor such as a cancer
- tumor resection e.g., tumor removal, for example, by surgery
- any method of systemic administration of the disclosed IRDye®700DX-CTC moiety or biomolecule can be used. Such methods may include for example, the use of catheters or implantable pumps to provide continuous infusion over a period of several hours to several days into the subject in need of treatment. Other methods include direct injection or infusion into the blood.
- the IRDye® 700DX-CTC moiety or biomolecule can be administered systemically, for example intravenously, intramuscularly, subcutaneously, intradermally, intraperitoneally, subcutaneously, or orally, to a subject having CTCs.
- the dosages of IRDye® 700DX-CTC moiety to be administered to a subject will depend on the nature of the composition and its active ingredients and its unwanted side effects (e.g., immune response against the moiety or biomolecule), the subject being treated and the type of condition being treated and the manner of administration.
- the dose will be a therapeutically effective amount, such as an amount sufficient to achieve a desired biological effect, for example an amount that is effective to reduce the number of CTCs in the subject, eliminate the CTCs, or decrease the chance of metastasis spread.
- exemplary dosages for administration to a subject for a single treatment can range from about 0.5 to 100 mg/60 kg of body weight, about 1 to 100 mg/60 kg of body weight, about 1 to 50 mg/60 kg of body weight, about 1 to 20 mg/60 kg of body weight, for example about 1 or 2 mg/60 kg of body weight.
- Treatments with the IRDye®700 DX-CTC moiety or biomolecule can be completed in a single day, or may be done repeatedly on multiple days with the same or a different dosage. Repeated treatments may be done on the same day, on successive days, or every 1-3 days, every 3-7 days, every 1-2 weeks, every 2-4 weeks, every 1-2 months, or at even longer intervals.
- the cells are contacted with one or more IRDye®700DX-CTC moiety or biomolecule, they are removed from the patient's body using an extracorporeal device wherein they are irradiated.
- blood containing the targeted cells is removed from the patient using a dialysis-like device and exposed to an irradiating light, e.g., at a wavelength of 660-740 nm.
- the cells in the blood are irradiated with a therapeutic dose of radiation at a wavelength of about 660-740 nm, e.g., about 660-700 nm, 670-690 nm, 660-680 nm. In preferred embodiments, the cells are irradiated with a therapeutic dose of radiation at a wavelength of about 680 nm.
- the cells are irradiated at a dose of at least 1 J cm ⁇ 2 , e.g., at least 1 J cm ⁇ 2 , at least 10 J cm ⁇ 2 , at least 30 J cm ⁇ 2 , at least 50 J cm ⁇ 2 , at least 100 J cm ⁇ 2 , or at least 500 J cm ⁇ 2 .
- the irradiating light is applied at, for example, 1-1000 J cm ⁇ 2 , 1-500 J cm ⁇ 2 , 10-100 J cm ⁇ 2 , or 10-50 J cm ⁇ 2 .
- the targeted cells in the blood can be irradiated one or more times.
- irradiation can be completed in a single day, or may be done repeatedly on multiple days with the same or a different dosage (such as irradiation at least 2 different times, 3 different times, 4 different times, 5 different times or 10 different times). Repeated irradiations may be done on the same day, on successive days, or every 1-3 days, every 3-7 days, every 1-2 weeks, every 2-4 weeks, every 1-2 months, or at even longer intervals.
- FIG. 1 An exemplary embodiment of the method and the device 100 is provided in FIG. 1 .
- the method and device provided herein can be used for performing extracorporeal CTC photodynamic therapy on a patient with circulating tumor cells using an extracorporeal circuit 110 , and a radiation chamber 150 housed in or separately from the extracorporeal device 100 .
- Blood is drawn from the patient, bearing an intravenous catheter, an arteriovenous fistula (AV) or a synthetic graft, etc., through the blood line 120 and transported to the fluid circuit 110 .
- a pump system 130 comprising pumps (e.g., peristaltic pumps) and tubing for the transport of flow from and to different unit sections.
- the blood pressure, temperature, pH, and/or other parameters are monitored.
- An anticoagulant can be added via, for example, injection to the blood in the circuit to prevent blood clotting.
- the IRDye® 700-CTC targeting agent e.g., IRDye® 700DX-CTC moiety or biomolecule
- the blood including the IRDye® 700DX labeled CTCs enter a phototherapy chamber 150 where the blood is exposed to irradiating light in the illumination circuit. The treated blood exits the phototherapy chamber 150 and is moving toward blood reintroducing line 121 .
- the therapeutic agent e.g., the unbound therapeutic agent
- the clearance chamber can be a dialyzer, a supernatant remover, a filter, or other physical methods for the clearance of the agent molecules.
- a light source provides an excitation light at a wavelength of about 660 nm to about 740 nm to the blood and labeled target CTCs as they pass through the phototherapy chamber. Exposure to the irradiating light induces the CTCs to undergo cell death, such as apoptosis, necrosis or autophagy.
- FIG. 2 Another exemplary embodiment of the method and the device 200 is provided in FIG. 2 .
- the methods herein can be used for performing extracorporeal CTC removal with the extracorporeal circuit 210 to reduce the number of CTCs before reintroducing the cleaned blood to the body.
- Blood is drawn from the patient through blood line 220 and transported to the extracorporeal circuit 210 .
- a pump system 230 comprising pump(s) (e.g. peristaltic pumps) and tubing for the transport of flow from and to different unit sections.
- the blood pressure, temperature, pH, and/or other parameters can be monitored.
- Chosen anticoagulant can be added via injection to the blood in the circuit to prevent blood clotting.
- the magnetic particle targeting agent (e.g., magnetic beads-CTC moiety) is added to the blood via the agent administration unit 240 with controlled flow rate and/or flow pressure.
- the blood including the targeted CTCs enter a magnetic influence chamber 250 where magnetic field is applied to the flow circuit.
- the magnetic field retains magnetic particle targeted CTCs from the blood flow before returning to the body through the reintroducing line 221 .
- the agent remnants (e.g., the unbound agents) are removed or reduced via the agent clearance chamber 270 .
- the clearance chamber can be a filter, a dialyzer, a supernatant remover, or other methods for the clearance of agent molecules.
- This example illustrates the application of photodynamic therapy using an IRDye® 700DX-targeting agent (e.g., EGF-700DX) and photoactivating light to kill targeted cells.
- an IRDye® 700DX-targeting agent e.g., EGF-700DX
- Cancer cells that overexpress the EGF receptor (e.g., A431 cells) were seeded in an in vitro culture system. The cells were incubated with the targeting agent EGF-700DX and exposed to irradiating light at a wavelength of 690 nm and at 8 J/cm 2 or 16 J/cm 2 .
- FIG. 3 shows a reduction in the number of targeted cells after exposure to irradiating light at 8 J/cm 2 or 16 J/cm 2 .
- FIGS. 3A-E show a reduction in the number of targeted cancer cells after exposure to irradiating light at 8 J/cm 2 or 16 J/cm 2 .
- FIGS. 3A-C are control data and FIGS. 3D-E show exposure to 8 J/cm 2 or 16 J/cm 2 , respectively.
- FIG. 3E shows significant morphology changes in cells treated with EGF-700DX and irradiating light at 16 J/cm 2 .
- FIG. 4 shows a reduction in the number of targeted cells in blood after exposure to irradiating light at 670 nm to 700 nm at 8 J/cm 2 or 16 J/cm 2 .
- FIGS. 4A-D shows a reduction in the number of targeted cancer cells in blood after exposure to irradiating light at 670 nm to 700 nm at 8 J/cm 2 or 16 J/cm 2 .
- FIGS. 4A-B are control data and FIGS. 4C-D show exposure to 8 J/cm 2 or 16 J/cm 2 , respectively.
- the targeting conjugate was flowed over the cells in a closed peristaltic pump setup at two different concentrations for two different time periods. Binding was evaluated at this step in the testing phase. No irradiation was added at this point.
- FIGS. 5A and 5B show that EGF-700DX successfully bound to the cultured cells.
- the flow rate of the conjugate concentration was 1.36 mL/min.
- A431 cells received either EGF-700DX (0.2 ⁇ M) for 15 min ( FIG. 5A ) or EGF-700DX (0.5 ⁇ M) for 5 min ( FIG. 5B ).
- this example shows that cancer cells were killed by labeling them with an IRDye®700DX-targeting agent (e.g., EGF-700DX) and exposing the labeled cells to photoactivating light. Furthermore, the presence of blood with the labeled cells did not affect the photodynamic method of irradiation. Additionally, the results illustrate that the IRDye® 700DX-targeting agent effectively binds to stationary cells within minutes.
- an IRDye®700DX-targeting agent e.g., EGF-700DX
- cancer cells that overexpress EGF e.g., A431 cells
- IRDye® 700DX-EGF probe at the test concentration and at a flow rate of 1.36 mL/min.
- the cells were washed to remove any unbound probe prior to irradiation.
- images of the cells were captured to determine the location of the probe and the extent of probe binding.
- the cells were then irradiated and imaged to identify morphology changes. 24 hours after irradiation, cell vitality (e.g., cell count and cell viability) was assessed using the NucleoCounter® NC-3000TM assay (Chemometec, Aller ⁇ d, Denmark).
- the data shows that the IRDye®700DX-EGF probe effectively bound to the cell surface of the EGF-positive cells after a brief incubation period. After incubation for 5 minutes with 0.5 ⁇ M probe ( FIG. 6A ) or 2.0 ⁇ M probe ( FIG. 6C ), the cells were irradiated at 4 J/cm 2 ( FIGS. 6B and 6D , respectively). No visual difference was observed between the treatments.
- the cells were incubated for 10 minutes with either 0.5 ⁇ M probe ( FIG. 7A ) or 2.0 ⁇ M probe ( FIG. 7C ) and irradiated at 16 J/cm 2 ( FIGS. 7B and 7D , respectively). Some change in morphology was detected immediately after irradiation. Apoptosis and/or necrosis was assessed 24 hours later using the cell vitality assay. The data shows that cell death was higher (e.g., lower % cell vitality) for treatments conducted at 16 J/cm 2 , such as for treatments 3, 4, 7, and 8 ( FIG. 8 ).
- this example shows the use of a photodynamic therapeutic method for initiating cell death in cancer cells overexpressing the EGF receptor.
- the experiments showed that the IRDye® 700DX-EGF probe selectively targeted the cancer cells which were then irradiated by a photoactivating light.
- the cell vitality assay showed that some of the treated cells underwent cell death.
- IRDye® 700DX-EGF probe and the IRDye® 700DX-panitumumab probe can induce cell death in A431 cells which are human epithelial cancer cells that overexpress the EGF receptor.
- EGF is the ligand for the EGF receptor and panitumumab is a fully human monoclonal antibody specific to the receptor.
- IRDye® 700DX targeting probes such as those based on proteins and antibodies, were able to target select cancer cells.
- the probe-bound cells underwent induced cell death upon photoactivation of the probe.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to methods and compositions for eliminating circulating tumor cells (CTCs) in a patient with or without solid tumors. In particular, the ex vivo method utilizes a photodynamic or magnetic targeting moiety that specifically binds to antigens expressed on the cell surface of CTCs.
Description
- This application claims priority to U.S. Provisional Patent Application Nos. 62/006,790, filed Jun. 2, 2014; 62/017,165, filed Jun. 25, 2014; 62/066,807, filed Oct. 21, 2014 and 62/082,052, filed Nov. 19, 2014, the teachings all of which are hereby incorporated by reference in their entireties for all purposes.
- Tumor metastasis is the process in which cancer cells spread from the site of a primary solid tumor to one or more other organs in the body. The cancer cells, such as circulating tumor cells (CTCs), shed from the solid tumor, translocate to distant tissues through blood and lymphatic vessels, and eventually proliferate and colonize to form metastases.
- Solid tumors are treated by therapies including surgery, radiotherapy, chemotherapy and targeted antibody therapy. Photoimmunotherapy using photosensitizing moiety or biomolecule-fluorophore conjugates has been been described as a possible treatment as well (see, e.g., U.S. Pat. No. 8,524,239).
- Photosensitizing antibody-fluorophore conjugates can utilize phthalocyanine dyes, such as IRDye® 700DX (LI-COR Biosciences, Lincoln, Nebr.) which has low sensitivity to photobleaching and is highly photostable (see, e.g., U.S. Pat. No. 7,005,518). These dyes can be conjugated to various biomolecules, such as antibodies or fragments thereof, antibodies, nanobodies, Affibodies®, diabodies, minibodies, antigens, ligands, proteins, peptides, carbohydrates, nucleic acids, small molecules, pseudovirion, etc. When exposed to excitation light, the phthalocyanine dye generates a cytotoxic singlet oxygen that can induce cell death, such as through apoptosis, necrosis or autophagy. Two types of reactions occur, Type I generates radicals and Type II generates singlet oxygen. Both radicals and singlet oxygen cause oxidative destruction of tissues. It has been shown that the administration of photodynamic therapy using IRDye® 700DX-anti-HER2+ antibodies can decrease the size of HER2+ solid tumors in a mouse model (Mitsunaga et al., Nat. Med., 2011, 17(12):1685-1691).
- Photodynamic therapy with photosensitizer can be performed with different forms of light sources (see, e.g., U.S. Pat. Nos. 5,976,175 and 8,175,687) to enable excitation light reaching different body locations. Whole body exposure with tanning bed (U.S. Pat. No. 6,896,693) or long-term treatment with wearable devices (U.S. Pat. No. 7,850,720) has been demonstrated. One of key factors in these kinds of methods is the extensive extinction of excitation light when passing through skins, soft tissues, or organs.
- Extracorporeal blood treatment eliminates the concern of light absorption through thick tissue layers. Currently, extracorporeal devices have been applied to patients for different treatment such as hemodialysis, extracorporeal oxygenation, CO2 removal, and apheresis, etc. The knowledge on extracorporeal circulation is thus well established and broadly applied. With the concept of extracorporeal light treatment on blood components, photopheresis utilizes separation of blood compositions and applies UV light to the concentrated part (e.g. white blood cells) before returning the recombined blood components to the patient. The photopheresis or extracorporeal photochemotherapy (see, e.g., U.S. Patent Publication Nos. 2003/0139466 and 2013/0197419) is an immunomodulating procedure that has been available for the treatment of cutaneous T-cell lymphoma such as mycosis fungoides or Sezary syndrome. Photopheresis is also used to treat conditions including graft-versus-host disease and organ transplant rejection. However, the rare CTCs shed from solid tumor into blood stream could not be separated and concentrated from blood effectively in the online extracorporeal device. The invention provides methods for extracorporeal treatment of CTCs.
- Clinically, the number of CTCs in a patient can be estimated via the CELLSEARCH® System (Janssen Diagnostics, LLC, Raritan, N.J.). The system utilizes ferrofluid nanoparticles with epithelial cell adhesion targeting antibodies to enumerate CTCs from the bulk of 7.5 ml blood samples. The CTCs are then distinguished with immunofluoresence dyes under a microscopic imaging system for diagnosis purpose. The system renders the monitoring of metastatic cancer patients throughout treatment to making informed clinical decisions.
- Current treatment methods for solid tumors are not effective at eliminating CTCs since they target only the cells of the tumor. There is a need for an effective method of reduce the number of CTC, and thereby reduce the risk of metastasis. The present invention satisfies this need and provides related advantages as well.
- In one aspect of the present invention, provided herein is a method for inducing apoptosis, necrosis or autophagy resulting in cell death of circulating tumor cells (CTCs) in a subject. The method comprises (a) administering to the subject's blood a therapeutically effective agent comprising a near-infrared phthalocyanine dye conjugated to an moiety or biomolecule that specifically binds to CTCs; (b) ex vivo irradiating the subject's blood with an appropriate excitation light in an amount to effectively induce apoptosis, necrosis and/or autophagy in the CTCs; and (c) re-introducing the treated blood into the subject.
- In some embodiments, the subject has a solid tumor or has had a solid tumor. In some instances, the solid tumor is a breast tumor, colorectal tumor, lung tumor, prostate tumor, ovarian tumor, pancreatic tumor, liver tumor, or bladder tumor.
- In some embodiments, the phthalocyanine dye is IRDye™ 700DX. In some embodiments, the light has a wavelength of about 660 to 740 nm.
- In some embodiments, the moiety or biomolecule specifically binds a CTC antigen. In some instances, the CTC antigen is selected from the group consisting of epithelial cell adhesion molecule (EpCAM), cytokeratin 8, cytokeratin 18, cytokeratin 19, E-cadherin, fibronectin, vimentin, MUC1, Her2, Twist, E-selectin, HSPG, CD44, octreoate, and others.
- In some embodiments, the therapeutically effective agent is administered at the time of anticoagulant administration with heparin, sodium citrate, thrombin inhibitors, prostacyclin and other prostanoids or other effective anticoagulants.
- In some embodiments, ex vivo irradiating is performed using an extracorporeal device.
- In some embodiments, un-bound therapeutically effective agent will be reduced or removed from blood via filtration or dialyzer or methods that involved molecular movement.
- In another aspect of the present invention, provided herein is a method of extracorporeal treatment of cancer in a subject having circulating tumor cells (CTCs). The method comprises: (a) intravenously administering a therapeutically effective agent comprising a phthalocyanine dye conjugated to a targeting moiety that specifically binds to CTCs; (b) ex vivo irradiating the subject's blood with a light (e.g., wavelength of 660 to 740 nm) in an amount to effectively induce apoptosis, necrosis or autophagy in CTCs; and (c) re-introducing the irradiated blood into the subject, thereby treating cancer in the subject.
- In some embodiments, step (b) and/or (c) are performed using an extracorporeal device.
- In some embodiments, the subject has undergone solid tumor resection.
- In some embodiments, the therapeutic agent is IRDye® 700DX. In some embodiments, the light has a wavelength of 660 to 740 nm.
- In some embodiments, the antibody specifically binds a CTC antigen. In some instances, the CTC antigen is selected from the group consisting of epithelial cell adhesion molecule (EpCAM), cytokeratin 8, cytokeratin 18, cytokeratin 19, E-cadherin, fibronectin, vimentin, MUC1, Her2, Twist, E-selectin, HSPG, CD44, octreoate, and others.
- In some embodiments, the therapeutically effective agent is administered at the time of anticoagulant administration with heparin, sodium citrate, thrombin inhibitors, prostacyclin and other prostanoids or other effective anticoagulants.
- In some embodiments, unbound therapeutically effective agent will be reduced or removed from blood via filtration or dialyzer or methods that involved molecular movement.
- In some embodiments, ex vivo irradiating is performed using an extracorporeal device.
- In another aspect of the present invention, provided herein is a method of extracorporeal treatment of cancer in a subject having CTCs. The method comprises: (a) administering a targeting agent comprising a magnetic particle conjugated to a biomolecule that specifically binds to CTCs; (b) ex vivo treatment of CTCs with an extracorporeal circuit to separate the particle-bound CTCs from blood stream with magnetic influence(s); and (c) re-introducing the treated blood into the subject, thereby mitigate the number of CTCs in the subject.
- In some embodiments, the treatment agent is introduced ex vivo through the extracorporeal device.
- In some embodiments, step (b) and/or (c) are performed using an extracorporeal device.
- In some embodiments, the subject has undergone solid tumor resection.
- In some embodiments, the antibody specifically binds a CTC antigen. In some instances, the CTC antigen is selected from the group consisting of epithelial cell adhesion molecule (EpCAM), cytokeratin 8, cytokeratin 18, cytokeratin 19, E-cadherin, fibronectin, vimentin, MUC1, Her2, Twist, E-selectin, HSPG, CD44, octreoate, and others.
- In some embodiments, the magnetic particle-targeted CTCs is removed or separated from blood via methods that involve molecular movement such as the influence of magnetic field(s).
- In yet another aspect of the present invention, provided herein is a therapeutically effective composition comprising a therapeutically effective agent comprising a phthanlocyanine dye conjugated to a circulating tumor cell (CTC) targeting moiety or biomolecule that specifically binds to a CTC.
- In some embodiments, the phthalocyanine dye is IRDye® 700DX.
- In some embodiments, the targeting moiety or biomolecule specifically binds a CTC antigen. In some instances, the CTC antigen is selected from the group consisting of epithelial cell adhesion molecule (EpCAM), cytokeratin 8, cytokeratin 18, cytokeratin 19, E-cadherin, fibronectin, vimentin, MUC1, Her2, Twist, E-selectin, HSPG, CD44, octreoate, and others.
- Other objects, features and advantages of the present invention will be apparent to one of skill in the art from the following detailed description and figures.
-
FIG. 1 is a schematic illustration of an exemplary embodiment in which the CTC extracorporeal photodynamic treatment is performed in the extracorporeal circuit. -
FIG. 2 illustrates an exemplary embodiment of the methods with CTC targeting magnetic particles which attaches to CTCs and renders the removal of CTCs with magnetic influence (e.g., a magnetic field). -
FIGS. 3A-E show a reduction in the number of targeted cancer cells after exposure to irradiating light at 8 J/cm2 or 16 J/cm2.FIGS. 3A-C show control data andFIGS. 3D-E show exposure to 8 J/cm2 or 16 J/cm2, respectively. -
FIGS. 4A-D show a reduction in the number of targeted cancer cells after exposure to irradiating light at 670 nm to 700 nm at 8 J/cm2 or 16 J/cm2 was made through 1 mm whole blood.FIGS. 4A-B present control data andFIGS. 4C-D show exposure to 8 J/cm2 or 16 J/cm2, respectively. -
FIGS. 5A-B show the IRDye® 700DX-EGF probe binding to A431 cells at two concentrations for two different time periods. A431 cells received a peristaltic flow of 1.36 mL/min of IRDye® 700DX-EGF at a concentration of 0.2 μM for 15 min (FIG. 5A ). A431 cells received a peristaltic flow of 1.36 mL/min of IRDye®700DX-EGF at a concentration of 0.5 μM for 5 min (FIG. 5B ). -
FIGS. 6A-6D show images of A431 cells incubated for 5 minutes with variable concentrations of IRDye 700DX®-EGF and then irradiated at 4 J/cm2.FIG. 6A shows the cells during the incubation of 0.5 μM of probe andFIG. 6B shows the cells after irradiation.FIG. 6C shows the cells incubated with 2 μM of probe.FIG. 6D shows these cells after irradiation. -
FIGS. 7A-7D provides images of A431 cells incubated for 10 minutes with variable concentrations of IRDye 700DX®-EGF and then irradiated at 16 J/cm2. Cells that were incubated with 0.5 μM of probe are shown inFIG. 7A .FIG. 7B shows these cells after irradiation.FIG. 7C shows cells treated with 2 μM of probe andFIG. 7D shows the cells after irradiation treatment. -
FIG. 8 illustrates that the percent cell vitality was lower for irradiation treatments of 16 J/cm2 (e.g.,treatments 3, 4, 7 and 8) compared to those of 4 J/cm2. Within the parameters tested, cell vitality was independent of probe concentration and probe incubation times. -
FIGS. 9A-C provides data of the statistical analysis performed.FIG. 9A shows the Box-Cox plot indicating that no transformation of data was required.FIG. 9B shows the normal probability plot of residuals that indicates that the residuals followed a normal distribution and were a good fit.FIG. 9C shows the ANOVA analysis. -
FIG. 10 provides a graph of the percent cell vitality of tumor cells treated with IRDye® 700DX-EGF or IRDye® 700DX-panitumumab and irradiated at 24 J/cm2. The cells were incubated for 5 minutes, 10 minutes or 20 minutes with the probe. -
FIGS. 11A-C provides images of the cells after irradiation at 24 J/cm2. The cells exhibited morphological blebbing which is associated with apoptosis and/or necrosis (see, white arrows). - The present invention relates to compositions and methods for the elimination of CTCs circulating in the blood of an individual. More particularly, the invention involves the use of a continuous-flow, extracorporeal device that treats the cells with IRDye®-targeting agents or magnetic particle-targeting agent to either trigger CTC cell death or enable the removal of CTCs from the blood stream before returning the treated blood to the body. Cell death of CTCs can be induced with an IRDye®700DX-targeting agent and the appropriate light exposure. In another aspect of the present invention, the CTCs can be removed from the blood using a magnetic particle-targeting agent and a magnetic influence.
- As used herein, the following terms have the meanings ascribed to them unless specified otherwise.
- The terms “a,” “an,” or “the” as used herein not only include aspects with one member, but also include aspects with more than one member. For instance, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a cell” includes a plurality of such cells and reference to “the agent” includes reference to one or more agents known to those skilled in the art, and so forth.
- The term “CTC targeting moiety” refers to any compound, molecule, or fragment thereof that can specifically bind to to the surface of a circulating tumor cell (CTC), e.g., any component present on the surface of a CTC, and/or tumor cell matter, e.g., any matter or component thereof that is derived, originated, or secreted from a tumor cell. Molecules that can be used as CTC targeting moieties include, but are not limited to, peptides, polypeptides, proteins, peptidomimetics, ligands, antigens, antibodies, antibody fragments (e.g., antigen binding fragments of antibodies), nanobodies, Affibodies®, diabodies, minibodies, carbohydrate-binding protein, e.g., a lectin, glycoproteins, glycoprotein-binding molecules, amino acids, carbohydrates (including mono-, di-, tri- and poly-saccharides), lipids, steroids, hormones, lipid-binding molecules, cofactors, nucleosides, nucleotides, nucleic acids (e.g., DNA or RNA, analogues and derivatives of nucleic acids, or aptamers), peptidoglycans, lipopolysaccharides, small molecules, and any combinations thereof.
- The term “antibody” refers to a polypeptide comprising at least a light chain or heavy chain immunoglobulin variable region which specifically recognizes and binds an epitope of an antigen, such as a tumor-specific protein. Antibodies are composed of a heavy and a light chain, each of which has a variable region, termed the variable heavy (VH) region and the variable light (VL) region. Together, the VH region and the VL region are responsible for binding the antigen recognized by the antibody. Antibodies include intact immunoglobulins and the variants and portions of antibodies well known in the art, such as Fab fragments, Fab′ fragments, F(ab)′2 fragments, single chain Fv proteins (“scFv”), and disulfide stabilized Fv proteins (“dsFv”). A scFv protein is a fusion protein in which a light chain variable region of an immunoglobulin and a heavy chain variable region of an immunoglobulin are bound by a linker, while in dsFvs, the chains have been mutated to introduce a disulfide bond to stabilize the association of the chains. The term also includes genetically engineered forms such as chimeric antibodies (for example, humanized murine antibodies), heteroconjugate antibodies (such as, bispecific antibodies). See also, Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, Ill.); Kuby, J., Immunology, 3rd Ed., W.H. Freeman & Co., New York, 1997.
- The term “IRDye® 700DX” or “IR700” refers to a dye having the preferred NHS ester linkage to allow for conjugation to a CTC targeting moiety. Typically, the CTC targeting moiety such as an antibody has a primary amine (e.g., an amino group) wherein the NHS ester and the amino group react to form an amide bond, linking the targeting moiety such as an antibody to 700DX. The NHS ester IRDye® 700DX has the following formula:
- The dye is commercially available from LI-COR (Lincoln, Nebr.). Amino-reactive IRDye® 700DX is a relatively hydrophilic dye and can be covalently conjugated with an antibody using the NHS ester of IRDye® 700DX. Other variations of IRDye 700Dx are disclosed in U.S. Pat. No. 7,005,518 (incorporated herein by reference), and those too are useful in the present invention. The carboxylate derivative has the following name and structure, silicate(5-), bis[N[3-[(hydroxy-.kappa.O)dimethylsilyl]propyl]-3-sulfo-N,N-bis(3-sulfopropyl)-1-propanaminiumato(4-)][6-[[[3-[(29H,31H-phthalocyanin-yl-.kappa.N29,.kappa.N30,.kappa.N31,.kappa.N32)oxy]propoxy]carbonyl]amino]hexanoato(3-)]-, sodium (1:5); CAS Registry Number: [1623074-46-3]:
- The term “photodynamic therapy,” “PDT” or “photoimmunotherapy” refers to a molecular targeted therapy that utilizes a target-specific photosensitizer agent, based on a near infrared (NIR) phthalocyanine dye, IRDye® 700DX, conjugated to a targeting moiety that specifically bind to a cell surface protein. For example, the cell surface protein such as EpCam is found specifically on circulating tumor cells, and thus photodynamic therapy can be used to kill such cells. Cell death of the cells can be induced when the IRDye® 700DX-anti-EpCam antibody binds to the cells and the cells are irradiated with the proper excitation light. For most application of PDT, the cytotoxic agent is produced by one of the two different processes called Type I or Type II PDT pathways. Type I generates radicals and Type II generates singlet oxygen. Both radicals and singlet oxygen cause oxidative destruction of tissues.
- Non-targeted options for PDT include sensitizers, porphyrins, chlorophylls and dyes.
- Non-limiting examples of useful photosensitizers include aminolevulinic acid (ALA), silicon phthalocyanine Pc 4, m-tetrahydroxyphenylchlorin (mTHPC), mono-L-aspartyl chlorine 6 (NPe6), and methylene blue. Commercially photosensitizers available for clinical use include Allumera®, Photofrin®, Visudyne®, Levulan®, Foscan®, Metvix®, Hexvix®, Cysview®, and Laserphyrin®. Other photosensitizers in development include Antrin®, Photochlor®, Photosens, Photrex®, Lumacan®, Cevira®, Visonac®, BF-200 ALA®, Amphinex®, and Azadipyrromethene®. Other classes of PDT agents include halogenated compounds, such as those described in, e.g., U.S. Patent Publication No. 2013/0231604; near-infrared light triggered upconversion nanoconstruct, such as those described in, e.g., Cui et al., ACS Nano, 2013, 7 (1), 676-688; hyaluronic acid-conjugated grapheme oxide/photosensitizer nanohybrids, such as those described in, e.g., Li et al., J. Mater. Chem. B, 2013, 1, 1678-1686, and aptamer-guided G-Quadruplex DNA carriers, such as those described in, e.g., Yuan et al., Angew. Chem. Int. Ed., 52: 13965-13969.
- The term “therapeutically effective amount” refers to an amount of a composition that alone, or together with an additional therapeutic agent(s) (such as a chemotherapeutic agent) is sufficient to achieve a desired effect in a subject, or in a cell, being treated with the composition. The effective amount of the therapeutic composition (such as an IRDye® 700DX-CTC targeting moiety) can be dependent on several factors, including, but not limited to the subject or cells being treated, the particular therapeutic agent, and the manner of administration of the therapeutic composition. For example, a therapeutically effective amount or concentration is sufficient to prevent advancement (such as metastasis), delay progression, or to cause regression of a disease, or which is capable of reducing symptoms caused by the disease, such as cancer. For instance, a therapeutically effective amount or concentration is sufficient to increase the survival time of a patient with a circulating tumor cell.
- The term “extracorporeal device” refers to an instrument that receives blood that is removed from a patient, processes (e.g., filters, purifies, treats, administers therapeutic agents to, etc.) the blood, and then returns the blood to the patient.
- The term “magnetic particles” includes beads, microbeads, and particles that a magnetic or paramagnetic.
- The term “individual,” “subject,” or “patient” typically refers to humans, but also to other animals including, e.g., other primates, rodents, canines, felines, equines, ovines, porcines, and the like.
- The methods provided herein can be used to treat a cancer patient post tumor resection (e.g., tumor excision by surgery) or treatment by reducing the circulating tumor cells (CTCs) in the blood, and thus, reducing the chance of metastatic spread. Photodynamic therapy (PDT) utilizes photosensitizers (e.g., photosensitizing agents or drugs) and light exposure to kill cancer cells. For example, the photosensitizing agent, porfimer sodium (e.g., Photofrin® is FDA approved for use in PDT to treat the symptoms of esophageal cancer and non-small cell lung cancer. Aminnolevulini acid (ALA or Levulan®) and methyl ester of ALA (Metvixia® cream) are FDA approved for skin or topical treatment for PDT. Most photosensitizing agents are not targeted and require irradiation of the whole body or a large region, which can result in unwanted cell death of normal tissues.
- Provided herein is a treatment method using an extracorporeal device that can circulate blood containing CTC targeted agents and to either induce CTC cell death (e.g., apoptosis, necrosis or autophagy) or to separate the CTCs from the blood returning to the body. The cell death is induced by photodynamic therapy method for CTCs that employs an IRDye®-targeting agent that can be excited by an irradiating light of a wavelength from 660 nm to about 740 nm. The irradiated blood can be returned (e.g., reintroduced) to the subject where the subject's immune system can recognize the apoptotic and/or necrotic cells and target them for removal. In some embodiments, the extracorporeal device is to circulate blood outside the body for the treatment of the agent targeted CTCs.
- A. Phthalocyanine Dye Conjugated to a Targeting Moiety
- Disclosed herein are targeted photosensitizing agents such as IRDye® 700DX-CTC moieties. Any targeting moiety (e.g., an antibody or fragment thereof, nanobody, Affibody®, diabody, minibody, antigen, ligand, protein, peptide, carbohydrate, nucleic acids, or small molecule) that specifically binds to a circulating tumor cell can be used.
- In some embodiments, the targeting moiety is specific for a protein expressed on the cell surface of a CTC. The cell surface protein can be selectively expressed on the surface of CTCs, and not other cells such as normal cells. In some instances, the cell surface protein is epithelial cell adhesion molecule (EpCAM), cytokeratin 8, cytokeratin 18, cytokeratin 19, E-cadherin, fibronectin, vimentin, MUC1, Her2, Twist, E-selectin, HSPG, CD44, octreoate, and others.
- One skilled in the art recognizes that cell surface protein sequences are publicly available and that making or purchasing antibodies specific for such proteins are routine. For example, EpCam antibodies are available from, e.g., Abeam® (Cambridge, Mass.), Cell Signaling Technology® (Danvers, Mass.), Santa Cruz Biotechnology® (Santa Cruz, Calif.), and other companies.
- The generation and selection of antibodies not already commercially available for targeting circulating tumor cells in accordance with the present invention can be accomplished several ways. For example, one way is to express and/or purify a polypeptide of interest (i.e., antigen) using protein expression and purification methods known in the art, while another way is to synthesize the polypeptide of interest using solid phase peptide synthesis methods known in the art. See, e.g., Guide to Protein Purification, Murray P. Deutcher, ed., Meth. Enzymol., Vol. 182 (1990); Solid Phase Peptide Synthesis, Greg B. Fields, ed., Meth. Enzymol., Vol. 289 (1997); Kiso et al., Chem. Pharm. Bull., 38:1192-99 (1990); Mostafavi et al., Biomed. Pept. Proteins Nucleic Acids, 1:255-60, (1995); and Fujiwara et al., Chem. Pharm. Bull., 44:1326-31 (1996). The purified or synthesized polypeptide can then be injected, for example, into mice or rabbits, to generate polyclonal or monoclonal antibodies. One skilled in the art will recognize that many procedures are available for the production of antibodies, for example, as described in Antibodies, A Laboratory Manual, Harlow and Lane, Eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1988). One skilled in the art will also appreciate that binding fragments or Fab fragments which mimic (e.g., retain the functional binding regions of) antibodies can also be prepared from genetic information by various procedures. See, e.g., Antibody Engineering: A Practical Approach, Borrebaeck, Ed., Oxford University Press, Oxford (1995); and Huse et al., J. Immunol., 149:3914-3920 (1992).
- Conjugation of IRDye® 700DX-CTC Targeting Moiety
- The CTC targeting agent (e.g., CTC targeting moiety) can be conjugated to a phthalocyanine dye, IRDye® 700DX (LI-COR, Lincoln, Nebr.). In some embodiments, CTC targeting moieties are labeled with IRDye® 700DX according to the manufacturer's protocols and kits. Detailed descriptions of methods for producing IRDye® 700DX-conjugates are found in, e.g., Kovar et al, Biochemistry—Faculty Publications, 2007, paper 9; Mitsunaga et al., Nature Medicine, 2011, 17:1685-1691; Peng et al., Proceedings of SPIE, 2006, 6097; U.S. Pat. Nos. 7,005,518 and 8,524,239; and U.S. Patent Application Publication No. 2013/0336995, the disclosures of each are herein incorporated in their entirety for all purposes.
- The IRDye®700DX-CTC moiety can be administered to the subject's blood in the blood circuit of the extracorporeal device. For instance, the targeting agent is injected into the blood that has exited the subject prior to treatment by the excitation light.
- In some embodiments, the dose of IRDye® 700DX-CTC moiety or biomolecle can be removed or cleared from the blood before returning to the subject. For instance, the removal or clearance methods can be mechanisms involved in molecular movement or attachment to isolate the agent from the blood stream so that the returning blood contains minimal amount of the therapeutic agent.
- In some embodiments, the IRDye® 700DX-CTC moiety or biomolecule can be administered systemically using any method known in the art, for example to subjects having a tumor, such as a cancer, or who has had tumor resection (e.g., tumor removal, for example, by surgery). One skilled in the art will appreciate that any method of systemic administration of the disclosed IRDye®700DX-CTC moiety or biomolecule can be used. Such methods may include for example, the use of catheters or implantable pumps to provide continuous infusion over a period of several hours to several days into the subject in need of treatment. Other methods include direct injection or infusion into the blood. Alternatively, the IRDye® 700DX-CTC moiety or biomolecule can be administered systemically, for example intravenously, intramuscularly, subcutaneously, intradermally, intraperitoneally, subcutaneously, or orally, to a subject having CTCs.
- The dosages of IRDye® 700DX-CTC moiety to be administered to a subject will depend on the nature of the composition and its active ingredients and its unwanted side effects (e.g., immune response against the moiety or biomolecule), the subject being treated and the type of condition being treated and the manner of administration. Generally the dose will be a therapeutically effective amount, such as an amount sufficient to achieve a desired biological effect, for example an amount that is effective to reduce the number of CTCs in the subject, eliminate the CTCs, or decrease the chance of metastasis spread.
- For intravenous administration of the IRDye® 700DX-CTC moiety or biomolecule, exemplary dosages for administration to a subject for a single treatment can range from about 0.5 to 100 mg/60 kg of body weight, about 1 to 100 mg/60 kg of body weight, about 1 to 50 mg/60 kg of body weight, about 1 to 20 mg/60 kg of body weight, for example about 1 or 2 mg/60 kg of body weight.
- Treatments with the IRDye®700 DX-CTC moiety or biomolecule can be completed in a single day, or may be done repeatedly on multiple days with the same or a different dosage. Repeated treatments may be done on the same day, on successive days, or every 1-3 days, every 3-7 days, every 1-2 weeks, every 2-4 weeks, every 1-2 months, or at even longer intervals.
- B. Irradiation of Targeted CTCs
- After the cells are contacted with one or more IRDye®700DX-CTC moiety or biomolecule, they are removed from the patient's body using an extracorporeal device wherein they are irradiated. In some embodiments, blood containing the targeted cells is removed from the patient using a dialysis-like device and exposed to an irradiating light, e.g., at a wavelength of 660-740 nm.
- In some embodiments, the cells in the blood are irradiated with a therapeutic dose of radiation at a wavelength of about 660-740 nm, e.g., about 660-700 nm, 670-690 nm, 660-680 nm. In preferred embodiments, the cells are irradiated with a therapeutic dose of radiation at a wavelength of about 680 nm. In some embodiments, the cells are irradiated at a dose of at least 1 J cm−2, e.g., at least 1 J cm−2, at least 10 J cm−2, at least 30 J cm−2, at least 50 J cm−2, at least 100 J cm−2, or at least 500 J cm−2. In other embodiments, the irradiating light is applied at, for example, 1-1000 J cm−2, 1-500 J cm−2, 10-100 J cm−2, or 10-50 J cm−2.
- The targeted cells in the blood can be irradiated one or more times. In some embodiments, irradiation can be completed in a single day, or may be done repeatedly on multiple days with the same or a different dosage (such as irradiation at least 2 different times, 3 different times, 4 different times, 5 different times or 10 different times). Repeated irradiations may be done on the same day, on successive days, or every 1-3 days, every 3-7 days, every 1-2 weeks, every 2-4 weeks, every 1-2 months, or at even longer intervals.
- C. Extracorporeal Photodynamic Therapy Device
- An exemplary embodiment of the method and the
device 100 is provided inFIG. 1 . - The method and device provided herein can be used for performing extracorporeal CTC photodynamic therapy on a patient with circulating tumor cells using an
extracorporeal circuit 110, and aradiation chamber 150 housed in or separately from theextracorporeal device 100. Blood is drawn from the patient, bearing an intravenous catheter, an arteriovenous fistula (AV) or a synthetic graft, etc., through theblood line 120 and transported to thefluid circuit 110. Apump system 130 comprising pumps (e.g., peristaltic pumps) and tubing for the transport of flow from and to different unit sections. In some embodiments, the blood pressure, temperature, pH, and/or other parameters are monitored. An anticoagulant can be added via, for example, injection to the blood in the circuit to prevent blood clotting. In some embodiments, the IRDye® 700-CTC targeting agent (e.g., IRDye® 700DX-CTC moiety or biomolecule) is added to the blood via theagent administration unit 140 with controlled flow rate and/or flow pressure. In some embodiments, the blood including the IRDye® 700DX labeled CTCs enter aphototherapy chamber 150 where the blood is exposed to irradiating light in the illumination circuit. The treated blood exits thephototherapy chamber 150 and is moving towardblood reintroducing line 121. In some embodiments, the therapeutic agent (e.g., the unbound therapeutic agent) is removed or reduced via theagent clearance chamber 170 before returning the body from theblood reintroducing line 121. The clearance chamber can be a dialyzer, a supernatant remover, a filter, or other physical methods for the clearance of the agent molecules. - Within the phototherapy chamber 150 a light source provides an excitation light at a wavelength of about 660 nm to about 740 nm to the blood and labeled target CTCs as they pass through the phototherapy chamber. Exposure to the irradiating light induces the CTCs to undergo cell death, such as apoptosis, necrosis or autophagy.
- D. Extracorporeal CTC Removal Device
- Another exemplary embodiment of the method and the
device 200 is provided inFIG. 2 . - The methods herein can be used for performing extracorporeal CTC removal with the
extracorporeal circuit 210 to reduce the number of CTCs before reintroducing the cleaned blood to the body. Blood is drawn from the patient throughblood line 220 and transported to theextracorporeal circuit 210. Apump system 230 comprising pump(s) (e.g. peristaltic pumps) and tubing for the transport of flow from and to different unit sections. In some embodiments, the blood pressure, temperature, pH, and/or other parameters can be monitored. Chosen anticoagulant can be added via injection to the blood in the circuit to prevent blood clotting. In some embodiments, the magnetic particle targeting agent (e.g., magnetic beads-CTC moiety) is added to the blood via theagent administration unit 240 with controlled flow rate and/or flow pressure. In some embodiments, the blood including the targeted CTCs enter amagnetic influence chamber 250 where magnetic field is applied to the flow circuit. The magnetic field retains magnetic particle targeted CTCs from the blood flow before returning to the body through the reintroducingline 221. In some embodiments, the agent remnants (e.g., the unbound agents) are removed or reduced via theagent clearance chamber 270. The clearance chamber can be a filter, a dialyzer, a supernatant remover, or other methods for the clearance of agent molecules. - The following examples are offered to illustrate, but not to limit, the claimed invention.
- This example illustrates the application of photodynamic therapy using an IRDye® 700DX-targeting agent (e.g., EGF-700DX) and photoactivating light to kill targeted cells.
- Cancer cells that overexpress the EGF receptor (e.g., A431 cells) were seeded in an in vitro culture system. The cells were incubated with the targeting agent EGF-700DX and exposed to irradiating light at a wavelength of 690 nm and at 8 J/cm2 or 16 J/cm2.
-
FIG. 3 shows a reduction in the number of targeted cells after exposure to irradiating light at 8 J/cm2 or 16 J/cm2.FIGS. 3A-E show a reduction in the number of targeted cancer cells after exposure to irradiating light at 8 J/cm2 or 16 J/cm2.FIGS. 3A-C are control data andFIGS. 3D-E show exposure to 8 J/cm2 or 16 J/cm2, respectively. In addition,FIG. 3E shows significant morphology changes in cells treated with EGF-700DX and irradiating light at 16 J/cm2. - To determine the effect of whole blood on the photodynamic method, cultured cancer cells were incubated with EGF-700DX. Blood was added to the culture dish to form a 1 mm layer on top of the cells but not in direct contact with them. The blood/cell chamber was exposed to irradiating light at a wavelength of 690 nm at 16 J/cm2. The photodynamic reaction between the EGF-700DX and the light occurred in the presence of the blood. There was a decrease in cell viability in the cells treated with irradiating light (e.g., 42% cell viability compared with 98.0-96.6% for controls).
-
FIG. 4 shows a reduction in the number of targeted cells in blood after exposure to irradiating light at 670 nm to 700 nm at 8 J/cm2 or 16 J/cm2.FIGS. 4A-D shows a reduction in the number of targeted cancer cells in blood after exposure to irradiating light at 670 nm to 700 nm at 8 J/cm2 or 16 J/cm2.FIGS. 4A-B are control data andFIGS. 4C-D show exposure to 8 J/cm2 or 16 J/cm2, respectively. - To determine the effect of flow rate and time on the ability of EGF-700DX to bind cultured cells (A431), the targeting conjugate was flowed over the cells in a closed peristaltic pump setup at two different concentrations for two different time periods. Binding was evaluated at this step in the testing phase. No irradiation was added at this point.
-
FIGS. 5A and 5B show that EGF-700DX successfully bound to the cultured cells. The flow rate of the conjugate concentration was 1.36 mL/min. A431 cells received either EGF-700DX (0.2 μM) for 15 min (FIG. 5A ) or EGF-700DX (0.5 μM) for 5 min (FIG. 5B ). - In summary, this example shows that cancer cells were killed by labeling them with an IRDye®700DX-targeting agent (e.g., EGF-700DX) and exposing the labeled cells to photoactivating light. Furthermore, the presence of blood with the labeled cells did not affect the photodynamic method of irradiation. Additionally, the results illustrate that the IRDye® 700DX-targeting agent effectively binds to stationary cells within minutes.
- A study was performed to optimize the conditions for IRDye®700DX-EGF based photodynamic therapy. In the experiment factors (e.g., parameters and variables) that contribute to the level of apoptosis and/or necrosis are tested. In particular, three factors with two conditions for each were evaluated in a 2×2×2 factorial design of experiments. The factors included: A) probe concentration at 0.5 μM and 2.0 μM, B) irradiation of 4 J/cm2 or 16 J/cm2, and C) probe incubation time of 5 minutes or 10 minutes. All possible treatment conditions were tested. Representative images of the treated cells are provided in
FIGS. 6A-6D and 7A-7D. - Briefly, cancer cells that overexpress EGF (e.g., A431 cells) were plated and incubated with the IRDye® 700DX-EGF probe at the test concentration and at a flow rate of 1.36 mL/min. After the incubation, the cells were washed to remove any unbound probe prior to irradiation. Afterwards, images of the cells were captured to determine the location of the probe and the extent of probe binding. The cells were then irradiated and imaged to identify morphology changes. 24 hours after irradiation, cell vitality (e.g., cell count and cell viability) was assessed using the NucleoCounter® NC-3000™ assay (Chemometec, Allerød, Denmark).
- The data shows that the IRDye®700DX-EGF probe effectively bound to the cell surface of the EGF-positive cells after a brief incubation period. After incubation for 5 minutes with 0.5 μM probe (
FIG. 6A ) or 2.0 μM probe (FIG. 6C ), the cells were irradiated at 4 J/cm2 (FIGS. 6B and 6D , respectively). No visual difference was observed between the treatments. - In the next set of conditions, the cells were incubated for 10 minutes with either 0.5 μM probe (
FIG. 7A ) or 2.0 μM probe (FIG. 7C ) and irradiated at 16 J/cm2 (FIGS. 7B and 7D , respectively). Some change in morphology was detected immediately after irradiation. Apoptosis and/or necrosis was assessed 24 hours later using the cell vitality assay. The data shows that cell death was higher (e.g., lower % cell vitality) for treatments conducted at 16 J/cm2, such as fortreatments 3, 4, 7, and 8 (FIG. 8 ). - Statistical analysis was performed to determine if data transformation was necessary. The Box-Cox plot was generated that showed that transformation was not required (
FIG. 9A ). The normal plot of residuals showed that the data fit into a straight line, thereby indicating that the residuals followed a normal distribution and were a good fit (FIG. 9B ). In addition, ANOVA information was obtained for the 2×2×2 factorial experiment (FIG. 9C ). The results demonstrate that the irradiation parameters had a significant effect on cell vitality. The other factors, such as the test probe concentrations and probe incubation times did not affect apoptosis and/or necrosis. - In summary, this example shows the use of a photodynamic therapeutic method for initiating cell death in cancer cells overexpressing the EGF receptor. The experiments showed that the IRDye® 700DX-EGF probe selectively targeted the cancer cells which were then irradiated by a photoactivating light. The cell vitality assay showed that some of the treated cells underwent cell death.
- This example illustrates that the IRDye® 700DX-EGF probe and the IRDye® 700DX-panitumumab probe can induce cell death in A431 cells which are human epithelial cancer cells that overexpress the EGF receptor. EGF is the ligand for the EGF receptor and panitumumab is a fully human monoclonal antibody specific to the receptor.
- A431 cells were plated and incubated with either probe for 5 minutes, 10 minutes or 20 minutes prior to washing and irradiation at 24 J/cm2. The IRDye® 700DX-EGF probe was used at a concentration of 0.5 μM in complete media and the IRDye® 700DX-panitumumab probe was used at a concentration of 0.1 μM. After irradiation, the cells were cultured at 37° C., 5% CO2 for approximately 24 hours. The NucleoCounter® NC-3000™ cell vitality assay (Chemometec, Allerød, Denmark) was performed. Table 1 provides cell numbers. Table 2 provides percent cell vitality.
-
TABLE 1 Cell Number (cells/mL) 5 minutes 10 minutes 20 minutes IRDye ® 700DX-EGF 1,000,000 1,000,000 1,500,00 IRDye ® 700DX-panitumumab 675,000 323,000 550,000 -
TABLE 2 Cell Vitality (%) 5 minutes 10 minutes 20 minutes IRDye ® 700DX-EGF 83.9% 85.2% 92.3% IRDye ® 700DX-panitumumab 44.2% 34% 31% - The data show a significant difference in the effectiveness of the probes at these conditions to induce cell death (Table 2 and
FIG. 10 ). The IRDye® 700DX-panitumumab averaged about 60% cell death and the IRDye® 700DX-EGF averaged about 20% over the time periods. The longer incubation time (e.g., 20 minutes vs. 5 minutes) with the antibody probe increased the number of cells undergoing cell death. The cell morphology also indicated that the treated cells were undergoing apoptosis, necrosis or autophagy (FIGS. 11A-11C ). Blebs which are typical of cells in apoptosis or necrosis were observed on the cell surface of the targeted cells. - This examples illustrates that IRDye® 700DX targeting probes, such as those based on proteins and antibodies, were able to target select cancer cells. The probe-bound cells underwent induced cell death upon photoactivation of the probe.
- Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, one of skill in the art will appreciate that certain changes and modifications may be practiced within the scope of the appended claims. In addition, each reference provided herein is incorporated by reference in its entirety to the same extent as if each reference was individually incorporated by reference.
Claims (20)
1. A method for inducing apoptosis and/or necrosis resulting in cell death of circulating tumor cells (CTCs) in a subject, the method comprising:
(a) administering to the subject's blood a therapeutically effective agent comprising a phthalocyanine dye conjugated to a CTC targeting moiety that specifically binds to CTCs;
(b) ex vivo irradiating the subject's blood with an appropriate excitation light in an amount to effectively induce apoptosis, necrosis or autophagy in the CTCs; and
(c) re-introducing the irradiated blood into the subject.
2. The method of claim 1 , wherein the phthalocyanine dye is IRDye® 700DX.
3. The method of claim 1 , wherein the targeting moiety is selected from the group consisting of an antibody or fragment thereof, nanobody, Affibody®, diabody, minibody, antigen, ligand, protein, peptide, carbohydrate, nucleic acids, and small molecule.
4. The method of claim 1 , wherein the targeting moiety specifically binds a CTC antigen.
5. The method of claim 1 , wherein the therapeutically effective agent is administered with an anticoagulant.
6. The method of claim 1 , wherein ex vivo irradiating is performed using an extracorporeal device.
7. The method of claim 1 , further comprising after step (a) removing the unbound therapeutically effective agent from the subject's blood by filtration or dialyzing.
8. A method of extracorporeal therapy for treating cancer in a subject having circulating tumor cells (CTCs), the method comprising:
(a) intravenously administering a therapeutically effective agent comprising a phthalocyanine dye conjugated to a CTC targeting moiety that specifically binds to CTCs;
(b) ex vivo irradiating the subject's blood with an appropriate excitation light in an amount to effectively induce apoptosis, necrosis or autophagy in the CTCs; and
(c) re-introducing the irradiated blood into the subject, thereby treating cancer in the subject.
9. The method of claim 8 , wherein the subject has undergone solid tumor resection.
10. The method of claim 8 , wherein the phthalocyanine dye is IRDye®700DX.
11. The method of claim 8 , wherein the targeting moiety is selected from the group consisting of an antibody or fragment thereof, nanobody, Affibody®, diabody, minibody, antigen, ligand, protein, peptide, carbohydrate, nucleic acids, and small molecule.
12. The method of claim 8 , wherein the targeting moiety specifically binds a CTC antigen.
13. The method of claim 8 , wherein the therapeutically effective agent is administered with an anticoagulant.
14. The method of claim 8 , wherein step (b) and/or (c) are performed using an extracorporeal device.
15. The method of claim 8 , further comprising after step (a) removing the unbound therapeutically effective agent from the subject's blood by filtration or dialyzing.
16. A method of extracorporeal treatment of cancer in a subject having circulating tumor cells (CTCs), the method comprising:
(a) administering to the subject a CTC targeting agent comprising magnetic particles conjugated to a targeting moiety that specifically binds to CTCs, wherein the targeting agent and the CTCs form a complex;
(b) ex vivo separating the blood from the complex using a magnetic field in an extracorporeal device; and
(c) re-introducing the blood into the subject, thereby treating cancer in the subject.
17. The method of claim 16 , wherein the targeting agent is introduced ex vivo by the extracorporeal device.
18. The method of claim 16 , wherein step (a) is performed using the extracorporeal device.
19. The method of claim 16 , wherein the subject has undergone solid tumor resection.
20. The method of claim 16 , wherein the targeting moiety specifically binds a CTC antigen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/728,204 US20150343060A1 (en) | 2014-06-02 | 2015-06-02 | Treatment of circulating tumor cells using an extracorporeal device |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462006790P | 2014-06-02 | 2014-06-02 | |
US201462017165P | 2014-06-25 | 2014-06-25 | |
US201462066807P | 2014-10-21 | 2014-10-21 | |
US201462082052P | 2014-11-19 | 2014-11-19 | |
US14/728,204 US20150343060A1 (en) | 2014-06-02 | 2015-06-02 | Treatment of circulating tumor cells using an extracorporeal device |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150343060A1 true US20150343060A1 (en) | 2015-12-03 |
Family
ID=54700548
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/728,304 Active 2035-12-28 US10588972B2 (en) | 2014-06-02 | 2015-06-02 | Phthalocyanine probes and uses thereof |
US14/728,204 Abandoned US20150343060A1 (en) | 2014-06-02 | 2015-06-02 | Treatment of circulating tumor cells using an extracorporeal device |
US14/728,247 Active US10064943B2 (en) | 2014-06-02 | 2015-06-02 | Therapeutic and diagnostic probes |
US16/046,748 Abandoned US20180339048A1 (en) | 2014-06-02 | 2018-07-26 | Therapeutic and Diagnostic Probes |
US16/751,850 Abandoned US20200179514A1 (en) | 2014-06-02 | 2020-01-24 | Phthalocyanine probes and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/728,304 Active 2035-12-28 US10588972B2 (en) | 2014-06-02 | 2015-06-02 | Phthalocyanine probes and uses thereof |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/728,247 Active US10064943B2 (en) | 2014-06-02 | 2015-06-02 | Therapeutic and diagnostic probes |
US16/046,748 Abandoned US20180339048A1 (en) | 2014-06-02 | 2018-07-26 | Therapeutic and Diagnostic Probes |
US16/751,850 Abandoned US20200179514A1 (en) | 2014-06-02 | 2020-01-24 | Phthalocyanine probes and uses thereof |
Country Status (7)
Country | Link |
---|---|
US (5) | US10588972B2 (en) |
EP (2) | EP3718570A1 (en) |
JP (3) | JP6741599B2 (en) |
CN (2) | CN106573054B (en) |
AU (1) | AU2015271830B2 (en) |
CA (1) | CA2950299A1 (en) |
WO (2) | WO2015187651A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10064943B2 (en) | 2014-06-02 | 2018-09-04 | Li-Cor, Inc. | Therapeutic and diagnostic probes |
US10537641B2 (en) | 2010-07-09 | 2020-01-21 | The Usa As Represented By The Secretary, Department Of Health And Human Services | Photosensitizing antibody-fluorophore conjugates |
US10830678B2 (en) | 2014-08-08 | 2020-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Photo-controlled removal of targets in vitro and in vivo |
US11013803B2 (en) | 2015-08-07 | 2021-05-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Near infrared photoimmunotherapy (NIR-PIT) of suppressor cells to treat cancer |
US11141483B2 (en) | 2015-08-18 | 2021-10-12 | Rakuten Medical, Inc. | Methods for manufacturing phthalocyanine dye conjugates and stable conjugates |
US11147875B2 (en) | 2015-08-18 | 2021-10-19 | Rakuten Medical, Inc. | Compositions, combinations and related methods for photoimmunotherapy |
US11678825B2 (en) * | 2018-10-04 | 2023-06-20 | Fenwal, Inc. | Methods and systems for collecting samples in a photopheresis procedure |
US11827721B2 (en) | 2018-03-02 | 2023-11-28 | Universität Zürich and ETH Zurich | Bioconjugates of antibodies and functionalized magnetic nanoparticles |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3242690B1 (en) * | 2015-01-06 | 2020-09-16 | De Haas, Anthony H. | Near-infrared fluorescent surgical dye markers |
US10066161B2 (en) | 2016-01-19 | 2018-09-04 | Nanosys, Inc. | InP quantum dots with GaP and AlP shells and methods of producing the same |
WO2017132639A1 (en) * | 2016-01-30 | 2017-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Light-activated anchoring of therapeutic factors to tissues |
CN107412794B (en) * | 2017-04-17 | 2019-01-04 | 中国医学科学院北京协和医院 | Double target spot imaging molecular probes and its preparation method and application |
GB201710097D0 (en) * | 2017-06-23 | 2017-08-09 | Univ Ulster | A sensitizer - peptide conjugate |
US20200405860A1 (en) * | 2018-03-09 | 2020-12-31 | The Jikei University | Conjugate of antibody targeting blood vessels and photosensitizer |
WO2019211843A1 (en) * | 2018-04-30 | 2019-11-07 | Bar-Ilan University | Polymeric core-shell particles |
WO2020032165A1 (en) | 2018-08-08 | 2020-02-13 | 国立大学法人 東京大学 | Conjugate of biotin variant dimer with phthalocyanine pigment |
CN109232906A (en) * | 2018-09-20 | 2019-01-18 | 福建师范大学 | Polyfluoroalkyl axial substituted silicon (IV) phthalocyanine-carbon nanotube supramolecular system and the preparation method and application thereof |
US20210386782A1 (en) * | 2018-10-18 | 2021-12-16 | The Brigham And Women`S Hospital, Inc. | Near Infrared Photoimmunotherapy |
CA3136294A1 (en) * | 2019-04-10 | 2020-10-15 | Coralluma Llc. | Ir700 nanocompositions for cardiac therapies and applications |
WO2021157655A1 (en) | 2020-02-05 | 2021-08-12 | 国立大学法人 東京大学 | Conjugate between antibody or peptide and phthalocyanine dye |
WO2022203000A1 (en) | 2021-03-25 | 2022-09-29 | 国立大学法人 東京大学 | Fusion protein between antigen-binding molecule and streptavidin variant |
CN113512089B (en) * | 2021-06-30 | 2023-06-13 | 兰州大学 | Polypeptide stabilizer of water-soluble quantum dot and application thereof |
CN117677701A (en) | 2021-07-29 | 2024-03-08 | 国立大学法人东京大学 | Fusion proteins of antigen binding molecules and streptavidin mutants |
TW202334238A (en) | 2021-11-30 | 2023-09-01 | 日商第一三共股份有限公司 | Protease-cleavable masked antibodies |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020114793A1 (en) * | 1999-04-20 | 2002-08-22 | Edelson Richard Leslie | Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells |
US20030139466A1 (en) * | 2001-11-29 | 2003-07-24 | Peritt David L. | Methods for pretreating a subject with extracorporeal photopheresis |
US20050112131A1 (en) * | 2002-03-25 | 2005-05-26 | Brian Pogue | Methods of adjuvant photodynamic therapy to enhance radiation sensitization |
US20060134001A1 (en) * | 2002-07-12 | 2006-06-22 | Frangioni John V | Conjugated infrared fluorescent substances for detection of cell death |
WO2007070680A2 (en) * | 2005-12-16 | 2007-06-21 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Optically detectable probes for identification and treatment of tumors |
US20080193431A1 (en) * | 2003-11-14 | 2008-08-14 | University Of Pennsylvania | Activatable photodynamic therapy agents |
US20090156976A1 (en) * | 2007-03-01 | 2009-06-18 | Martin Korbling | Devices and Methods for Extracorporeal Ablation of Circulating Cells |
US20100216226A1 (en) * | 2009-02-25 | 2010-08-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US20120010558A1 (en) * | 2010-07-09 | 2012-01-12 | Services, National Institutes of Health | Photosensitizing antibody-fluorophore conjugates |
US20120228568A1 (en) * | 2011-03-10 | 2012-09-13 | Joseph Alfred Leon | Nail/Bolt Slide Hammer Extractor |
US20130039860A1 (en) * | 2010-10-20 | 2013-02-14 | Li-Cor, Inc. | Fluorescent imaging with substituted cyanine dyes |
WO2013009475A9 (en) * | 2011-07-11 | 2013-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Photosensitizing antibody-phuorophore conjugates |
US20130131423A1 (en) * | 2011-04-12 | 2013-05-23 | Tianxin Wang | Methods to detect and treat diseases |
US20140161725A1 (en) * | 2011-09-10 | 2014-06-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Molecular Imaging of Cancer Cells In Vivo |
US8889835B2 (en) * | 2005-04-06 | 2014-11-18 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
US20160228568A1 (en) * | 2013-09-18 | 2016-08-11 | Aura Biosciences, Inc. | Virus-like particle conjugates for diagnosis and treatment of tumors |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3672292A (en) * | 1970-09-22 | 1972-06-27 | Vacu Blast Corp | Blast-room for abrasive blasting system |
US6667156B2 (en) * | 1995-12-27 | 2003-12-23 | Uab Research Foundation | Diagnosis and treatment of neuroectodermal tumors |
US7230088B2 (en) * | 2001-07-03 | 2007-06-12 | Mallinckrodt, Inc. | Compounds for dual photodiagnosis and therapy |
US7597878B2 (en) | 2000-09-19 | 2009-10-06 | Li-Cor, Inc. | Optical fluorescent imaging |
DE60116510T2 (en) | 2000-09-19 | 2006-07-13 | Li-Cor, Inc., Lincoln | cyanine |
US20030105299A1 (en) | 2001-10-17 | 2003-06-05 | Mallinckrodt Inc. | Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications |
US7597876B2 (en) | 2007-01-11 | 2009-10-06 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
US7005518B2 (en) | 2002-10-25 | 2006-02-28 | Li-Cor, Inc. | Phthalocyanine dyes |
US7119168B2 (en) | 2002-11-18 | 2006-10-10 | Bioprospecting Nb Inc. | Paralytic peptide for use in neuromuscular therapy |
DK1812031T3 (en) | 2004-11-01 | 2015-09-14 | Univ California | Compositions and methods for the modification of biomolecules |
CN100362103C (en) * | 2004-12-21 | 2008-01-16 | 苏州大学 | Human epidermis factor nucleic sequence and use thereof |
US20060204443A1 (en) | 2005-03-11 | 2006-09-14 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for tumor treatment using dendrimer conjugates |
US8227621B2 (en) | 2005-06-30 | 2012-07-24 | Li-Cor, Inc. | Cyanine dyes and methods of use |
WO2008005942A2 (en) | 2006-06-30 | 2008-01-10 | The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services. | Activatable probes and methods of use |
DK2145189T3 (en) | 2007-05-08 | 2016-06-06 | Us Health | Papillomavirus pseudo viruses for the detection and treatment of tumors |
EP2211913A4 (en) * | 2007-10-12 | 2010-12-22 | Transmolecular Inc | Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors |
WO2009105209A1 (en) * | 2008-02-19 | 2009-08-27 | Health Research, Inc. | Silica nanoparticles postloaded with photosensitizers for drug delivery in photodynamic therapy |
KR101595138B1 (en) * | 2008-02-27 | 2016-02-18 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Rgd(bacterio)chlorophyll conjugates for photodynamic therapy and imaging of necrotic tumors |
EP2210590A1 (en) | 2009-01-26 | 2010-07-28 | Academisch Medisch Centrum | Drug delivery system for use in the treatment of vascular and vessel-related pathologies |
WO2010108125A2 (en) | 2009-03-19 | 2010-09-23 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
WO2011008814A2 (en) | 2009-07-14 | 2011-01-20 | Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation | Multiplexed measurement of exogenous and endogenous dna |
CA2768460A1 (en) | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Antagonists, uses & methods for partially inhibiting tnfr1 |
EP2459191A1 (en) | 2009-07-31 | 2012-06-06 | OSI Pharmaceuticals, LLC | Mtor inhibitor and angiogenesis inhibitor combination therapy |
US20130224115A1 (en) * | 2010-04-01 | 2013-08-29 | Baylor College Of Medicine | Non-radioactive agents for neuroblastoma imaging |
CN106957356B (en) | 2010-05-11 | 2021-05-25 | 弗雷德哈钦森癌症研究中心 | Chlorotoxin variants, conjugates, and methods of use thereof |
WO2012024396A2 (en) * | 2010-08-17 | 2012-02-23 | Rutgers, The State University Of New Jersey | Compositions and methods for delivering nucleic acid molecules and treating cancer |
US20130287688A1 (en) | 2010-11-18 | 2013-10-31 | Xtuit Pharmaceuticals, Inc. | Novel compositions and uses of anti-hypertension agents for cancer therapy |
WO2012078877A2 (en) | 2010-12-08 | 2012-06-14 | Invicro, Llc | Estimating pharmacokinetic parameters in imaging |
CN102526055B (en) * | 2010-12-24 | 2014-01-01 | 北京工业大学 | Application of cyclohexanediamine hypocrelline B in photodynamic anti-tumor medicaments |
US20130116408A1 (en) | 2011-11-05 | 2013-05-09 | Aura Biosciences, Inc. | Virion Derived Protein Nanoparticles For Delivering Radioisotopes For The Diagnosis And Treatment Of Malignant And Systemic Disease And The Monitoring Of Therapy |
GB201306627D0 (en) * | 2013-04-11 | 2013-05-29 | Thompson Richard | Marker |
US10588972B2 (en) | 2014-06-02 | 2020-03-17 | Li-Cor, Inc. | Phthalocyanine probes and uses thereof |
-
2015
- 2015-06-02 US US14/728,304 patent/US10588972B2/en active Active
- 2015-06-02 AU AU2015271830A patent/AU2015271830B2/en not_active Ceased
- 2015-06-02 CA CA2950299A patent/CA2950299A1/en not_active Abandoned
- 2015-06-02 JP JP2016571079A patent/JP6741599B2/en active Active
- 2015-06-02 WO PCT/US2015/033715 patent/WO2015187651A1/en active Application Filing
- 2015-06-02 WO PCT/US2015/033759 patent/WO2015187677A1/en active Application Filing
- 2015-06-02 CN CN201580029000.7A patent/CN106573054B/en active Active
- 2015-06-02 EP EP20166311.9A patent/EP3718570A1/en not_active Withdrawn
- 2015-06-02 EP EP15803454.6A patent/EP3148583B1/en active Active
- 2015-06-02 US US14/728,204 patent/US20150343060A1/en not_active Abandoned
- 2015-06-02 CN CN202110310088.7A patent/CN112999347A/en active Pending
- 2015-06-02 US US14/728,247 patent/US10064943B2/en active Active
-
2018
- 2018-07-26 US US16/046,748 patent/US20180339048A1/en not_active Abandoned
-
2020
- 2020-01-24 US US16/751,850 patent/US20200179514A1/en not_active Abandoned
- 2020-04-28 JP JP2020079840A patent/JP2020125343A/en active Pending
-
2021
- 2021-10-27 JP JP2021175445A patent/JP2022023175A/en active Pending
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020114793A1 (en) * | 1999-04-20 | 2002-08-22 | Edelson Richard Leslie | Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells |
US20030139466A1 (en) * | 2001-11-29 | 2003-07-24 | Peritt David L. | Methods for pretreating a subject with extracorporeal photopheresis |
US20050112131A1 (en) * | 2002-03-25 | 2005-05-26 | Brian Pogue | Methods of adjuvant photodynamic therapy to enhance radiation sensitization |
US20060134001A1 (en) * | 2002-07-12 | 2006-06-22 | Frangioni John V | Conjugated infrared fluorescent substances for detection of cell death |
US20080193431A1 (en) * | 2003-11-14 | 2008-08-14 | University Of Pennsylvania | Activatable photodynamic therapy agents |
US8133482B2 (en) * | 2003-11-14 | 2012-03-13 | The Trustees Of The University Of Pennsylvania | Activatable photodynamic therapy agents |
US8889835B2 (en) * | 2005-04-06 | 2014-11-18 | Immunomedics, Inc. | Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites |
WO2007070680A2 (en) * | 2005-12-16 | 2007-06-21 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Optically detectable probes for identification and treatment of tumors |
US20090156976A1 (en) * | 2007-03-01 | 2009-06-18 | Martin Korbling | Devices and Methods for Extracorporeal Ablation of Circulating Cells |
US20100216226A1 (en) * | 2009-02-25 | 2010-08-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US20120010558A1 (en) * | 2010-07-09 | 2012-01-12 | Services, National Institutes of Health | Photosensitizing antibody-fluorophore conjugates |
US20140120119A1 (en) * | 2010-07-09 | 2014-05-01 | The United States of America, as rep. by the Secretary, Dept. of Health and Human Services | Photosensitizing antibody-fluorophore conjugates |
US20130039860A1 (en) * | 2010-10-20 | 2013-02-14 | Li-Cor, Inc. | Fluorescent imaging with substituted cyanine dyes |
US20120228568A1 (en) * | 2011-03-10 | 2012-09-13 | Joseph Alfred Leon | Nail/Bolt Slide Hammer Extractor |
US20130131423A1 (en) * | 2011-04-12 | 2013-05-23 | Tianxin Wang | Methods to detect and treat diseases |
WO2013009475A9 (en) * | 2011-07-11 | 2013-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Photosensitizing antibody-phuorophore conjugates |
US20140161725A1 (en) * | 2011-09-10 | 2014-06-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Molecular Imaging of Cancer Cells In Vivo |
US20160228568A1 (en) * | 2013-09-18 | 2016-08-11 | Aura Biosciences, Inc. | Virus-like particle conjugates for diagnosis and treatment of tumors |
Non-Patent Citations (1)
Title |
---|
"In Vivo Magnetic Enrichment Photoacoustic Diagnosis and Photothermal Purging of Infected Blood Using Multifunctional Gold and Magnetic Nanoparticles" Ekateriena GalahzhaEvegeny Shashkov,Justafa Sarimollaoglu,Karen Beenken,Alexei Basnakian,Mark Shirtliff,JonWoo Kim,Mark Smeltzer,Vladimir Zharov PLOS ONE September 2012 Vol 7 Issue 9 e45557 pp1-19 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11364298B2 (en) | 2010-07-09 | 2022-06-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Photosensitizing antibody-fluorophore conjugates |
US10537641B2 (en) | 2010-07-09 | 2020-01-21 | The Usa As Represented By The Secretary, Department Of Health And Human Services | Photosensitizing antibody-fluorophore conjugates |
US10538590B2 (en) | 2010-07-09 | 2020-01-21 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Photosensitizing antibody-fluorophore conjugates |
US11364297B2 (en) | 2010-07-09 | 2022-06-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Photosensitizing antibody-fluorophore conjugates |
US10588972B2 (en) | 2014-06-02 | 2020-03-17 | Li-Cor, Inc. | Phthalocyanine probes and uses thereof |
US10064943B2 (en) | 2014-06-02 | 2018-09-04 | Li-Cor, Inc. | Therapeutic and diagnostic probes |
US10830678B2 (en) | 2014-08-08 | 2020-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Photo-controlled removal of targets in vitro and in vivo |
US11781955B2 (en) | 2014-08-08 | 2023-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Photo-controlled removal of targets in vitro and in vivo |
US11013803B2 (en) | 2015-08-07 | 2021-05-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Near infrared photoimmunotherapy (NIR-PIT) of suppressor cells to treat cancer |
US11141483B2 (en) | 2015-08-18 | 2021-10-12 | Rakuten Medical, Inc. | Methods for manufacturing phthalocyanine dye conjugates and stable conjugates |
US11147875B2 (en) | 2015-08-18 | 2021-10-19 | Rakuten Medical, Inc. | Compositions, combinations and related methods for photoimmunotherapy |
US11154620B2 (en) | 2015-08-18 | 2021-10-26 | Rakuten Medical, Inc. | Compositions, combinations and related methods for photoimmunotherapy |
US11827721B2 (en) | 2018-03-02 | 2023-11-28 | Universität Zürich and ETH Zurich | Bioconjugates of antibodies and functionalized magnetic nanoparticles |
US11678825B2 (en) * | 2018-10-04 | 2023-06-20 | Fenwal, Inc. | Methods and systems for collecting samples in a photopheresis procedure |
Also Published As
Publication number | Publication date |
---|---|
EP3148583A4 (en) | 2018-01-17 |
CN112999347A (en) | 2021-06-22 |
AU2015271830B2 (en) | 2020-03-05 |
JP2017524659A (en) | 2017-08-31 |
EP3148583A1 (en) | 2017-04-05 |
JP6741599B2 (en) | 2020-08-19 |
AU2015271830A1 (en) | 2016-12-22 |
JP2020125343A (en) | 2020-08-20 |
US20150343084A1 (en) | 2015-12-03 |
WO2015187651A1 (en) | 2015-12-10 |
CA2950299A1 (en) | 2015-12-10 |
US20150374819A1 (en) | 2015-12-31 |
EP3148583B1 (en) | 2020-04-29 |
US20200179514A1 (en) | 2020-06-11 |
US20180339048A1 (en) | 2018-11-29 |
JP2022023175A (en) | 2022-02-07 |
EP3718570A1 (en) | 2020-10-07 |
CN106573054A (en) | 2017-04-19 |
CN106573054B (en) | 2021-04-13 |
WO2015187677A1 (en) | 2015-12-10 |
US10064943B2 (en) | 2018-09-04 |
US10588972B2 (en) | 2020-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20150343060A1 (en) | Treatment of circulating tumor cells using an extracorporeal device | |
Sato et al. | Photoinduced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies: a mechanism of cancer cell cytotoxicity after near-infrared photoimmunotherapy | |
JP7425026B2 (en) | Phthalocyanine dye conjugate and its preservation method | |
Fernandes et al. | Photoimmunoconjugates: novel synthetic strategies to target and treat cancer by photodynamic therapy | |
JP2021105054A (en) | Photosensitizing antibody-fluorophore conjugates | |
US8057418B2 (en) | Devices and methods for extracorporeal ablation of circulating cells | |
EP2784082B1 (en) | Disease site-delivering pharmaceutical compositions comprising paclitaxel. | |
US11369425B2 (en) | Lactoferrin-conjugated nanoparticle complex and use thereof | |
US20160058937A1 (en) | Blood cleansing and apparatus & method | |
Kim et al. | A novel therapeutic strategy of multimodal nanoconjugates for state-of-the-art brain tumor phototherapy | |
US20180169319A1 (en) | Treatment of cancer by manipulating the immune system | |
Nishimura et al. | Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT | |
Hirata et al. | Near‐infrared photoimmunotherapy (NIR‐PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes | |
US20230226201A1 (en) | Drug conjugate having enhanced drug delivery and internalization efficiency | |
Liang et al. | Hybrid membrane-camouflaged hollow prussian blue nanoparticles for shikonin loading and combined chemo/photothermal therapy of metastatic TNBC | |
US20150122738A1 (en) | Blood Cleansing System & Method | |
Peng et al. | Photoimmunotherapy: A New Paradigm in Solid Tumor Immunotherapy | |
Kumari et al. | Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics | |
JP7216435B2 (en) | Conjugates of blood vessel-targeting antibodies and photosensitizers | |
Hu et al. | Albumin-Based Cyanine Crizotinib Conjugate Nanoparticles for NIR-II Imaging-Guided Synergistic Chemophototherapy | |
US9808526B2 (en) | Pharmaceutical kit and methods for cancer treatment via intracavity delivery and for preparing metal nanoparticle-antibody fragment conjugate | |
JP4696259B2 (en) | Novel photosensitive drug and method for producing the same | |
Kobayashi | Illuminating the cancer-targeting potential of near-infrared photoimmunotherapy | |
US20240100053A1 (en) | Pharmaceutical composition | |
WO2022107573A1 (en) | Pharmaceutical composition to be used in photoimmunotherapy targeting tumor microenvironment, marker for confirming therapeutic effect, and test method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: LI-COR, INC., NEBRASKA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOVAR, JOY L.;WANG, HAN-WEI;SIGNING DATES FROM 20150616 TO 20150622;REEL/FRAME:035899/0663 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: RAKUTEN MEDICAL, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LI-COR, INC.;REEL/FRAME:055238/0885 Effective date: 20201230 |